49. 全身性エリテマトーデス Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
/kg CNTO 136
Centocor Research & Development, Inc.
2007 Phase 1 NCT01702740 -
2-deoxy-2 [F-18] fluoro-2-d-glucose
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 - NCT00029926 United States;
A-623
Anthera Pharmaceuticals
2011 Phase 2 NCT01305746 Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States;
2010 Phase 2 NCT01162681 Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States;
ABBV-105
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-HU Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-ES Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
ABETIMUS SODIUM
AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
2009 - EUCTR2008-004852-62-IT Italy;
ABR-215757
Active Biotech Research AB
2009 - EUCTR2009-011245-55-SE Denmark;Sweden;
2009 - EUCTR2009-011245-55-DK Denmark;Sweden;
ABT-199
AbbVie (prior sponsor, Abbott)
2012 Phase 1 NCT01686555 Germany;Mexico;Puerto Rico;United States;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-HU Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-ES Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AC0058TA
ACEA Therapeutics, Inc.
2018 Phase 1 NCT03878303 United States;
ACM
Manuel Praga Terente
2010 - EUCTR2009-017273-38-ES Spain;
ACT-334441
ACTELION Pharmaceuticals Ltd
2015 Phase 2 EUCTR2014-002984-14-BG Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States;
IDORSIA PHARMACEUTICALS LTD
2019 Phase 2 EUCTR2018-001808-11-IT Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd
2020 Phase 2 EUCTR2018-001808-11-GR Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-PL Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-HU Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-FR Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-ES Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-DE Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-BG Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2018-001808-11-GB Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
AGS-009
Argos Therapeutics
2009 Phase 1 NCT00960362 Sweden;United States;
AIDSVAX® B/E
National Institute of Allergy and Infectious Diseases (NIAID)
2018 Phase 1 NCT03618056 United States;
AKBM-3031
Aker Biomarine Antarctic AS
2018 - NCT03626311 Canada;United States;
ALDESLEUCHINA
ILTOO PHARMA
2017 Phase 2 EUCTR2016-000488-17-IT Austria;Bulgaria;France;Italy;Portugal;Spain;
ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2017-001400-29-FR France;
ALPN-101
Alpine Immune Sciences, Inc.
2022 Phase 2 EUCTR2020-004047-86-HU France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 NCT04835441 Korea, Republic of;Poland;United States;
2021 Phase 2 EUCTR2020-004047-86-PL France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-ES France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
- Phase 2 EUCTR2020-004047-86-FR France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
ALX-0061
Ablynx
2015 Phase 2 NCT02437890 Argentina;Chile;Czech Republic;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
ALX-0061 150 mg/mL
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-PT Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-ES Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
AMG 557
Amgen
2012 Phase 1 NCT01683695 Australia;Denmark;France;Germany;Malaysia;Singapore;Taiwan;United Kingdom;United States;
2008 Phase 1 NCT00774943 Canada;United States;
2006 Phase 1 NCT02391259 United Kingdom;United States;
AMG 570
AMGEN INC.
2019 Phase 2 EUCTR2019-000328-16-IT Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
Amgen
2016 Phase 1 NCT02618967 United States;
Amgen Inc
2021 Phase 2 EUCTR2019-000328-16-GR Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000328-16-PT Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
AMG 592
AMGEN INC.
2021 Phase 2 EUCTR2020-003509-72-IT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
Amgen Inc.
2021 Phase 2 EUCTR2020-003509-72-PL Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-GR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-FR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-ES Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-BG Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-AT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
AMG 623
Amgen
2005 Phase 1 NCT02411136 -
2004 Phase 1 NCT02443506 -
AMG 811
Amgen
2009 Phase 1 NCT00818948 France;Hong Kong;Malaysia;Mexico;Singapore;United States;
2007 Phase 1 NCT02291588 -
AMG592
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-002564-40-DE France;Germany;Poland;United States;
AMG811
Amgen
2010 Phase 1 NCT01164917 United States;
ASF-1096 Cream
Astion Danmark A/S
2007 - EUCTR2006-001062-17-SE Sweden;United Kingdom;
Astion Pharma A/S
2007 - EUCTR2007-004635-29-SE Denmark;Spain;Sweden;
2007 - EUCTR2007-004635-29-DK Denmark;Spain;Sweden;
Abatacept
Bristol Myers Squibb International Corporation
2006 - EUCTR2004-004051-19-IT Germany;Italy;Sweden;United Kingdom;
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
2005 Phase 2 NCT00119678 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
Oklahoma Medical Research Foundation
2014 Phase 2 NCT02270957 United States;
Abatacept also known as Orencia also known as CTLA4-Ig
University of California, Los Angeles
2015 Phase 1/Phase 2 NCT02429934 United States;
Abetimus Sodium
La Jolla Pharmaceutical Company
2008 - EUCTR2006-000674-73-BG Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2006 Phase 3 EUCTR2006-000674-73-SK Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain;
Abetimus sodium
LA JOLLA PHARMACEUTICAL COMPANY
2008 - EUCTR2006-000674-73-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
Abetimus sodium (LJP 394)
La Jolla Pharmaceutical Company
2006 Phase 2 NCT00390091 United States;
2004 Phase 3 NCT00089804 Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States;
2001 Phase 3 NCT00035308 Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
Acazicolcept
Alpine Immune Sciences, Inc.
2022 Phase 2 EUCTR2020-004047-86-HU France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-PL France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-ES France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
- Phase 2 EUCTR2020-004047-86-FR France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
Acetaminophen
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
Acetaminophen/Paracetamol
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Acthar
Mallinckrodt
2013 Phase 4 NCT01753401 United States;
Acthar Gel
Mallinckrodt
2016 Phase 4 NCT02953821 Argentina;Chile;Colombia;Mexico;Peru;United States;
Acthar high dose (80 U)
NYU Langone Health
2016 Phase 4 NCT02779153 United States;
Acthar low dose (40 U)
NYU Langone Health
2016 Phase 4 NCT02779153 United States;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Administration of methylprednisolone, paracetamol and dexchlorpheniramine
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Aldesleukin
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
Allogeneic MSC (AlloMSC)
Nanjing Medical University
2007 Phase 1/Phase 2 NCT00698191 China;
Allogeneic Stem Cell Transplantation
Northwestern University
2004 Phase 1 NCT00278590 United States;
Allogeneic bone marrow transplant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Alpha-tocopherol
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Anifrolumab
ASTRAZENECA AB
2015 Phase 3 EUCTR2014-004633-96-IT Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca
2021 Phase 3 NCT04931563 China;Hong Kong;Korea, Republic of;Philippines;Taiwan;Thailand;
2021 Phase 1 NCT05001698 China;
2021 - NCT04750057 -
2017 Phase 3 JPRN-JapicCTI-173544 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2017 Phase 2 NCT02962960 Hungary;Korea, Republic of;Poland;United States;
2016 Phase 3 NCT02794285 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 JPRN-JapicCTI-153064 Japan, Asia except Japan, North America, South America, Europe, Africa;
2015 Phase 3 NCT02446912 Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 NCT02446899 Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
AstraZeneca AB
2017 Phase 3 EUCTR2016-000625-39-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-RO Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-PL Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-HU Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-GB Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-DE Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004632-19-LT Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-CZ Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
Astrazeneca AB
2016 Phase 2 EUCTR2016-003246-93-HU Hungary;Korea, Republic of;Poland;United States;
Hibi Kazushige
2021 Phase 3 JPRN-jRCT2071210076 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russia;Spain;Ukraine;United Kingdom;United States;
MedImmune LLC
2013 Phase 2 NCT01753193 Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2012 Phase 2 NCT01438489 Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
2014 Phase 2 EUCTR2012-004619-30-BG Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-HU Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
Oklahoma Medical Research Foundation
2021 Early Phase 1 NCT04726553 United States;
Anti BAFF (B cell activating factor)
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Anti LP40 antibody, subclass IgG4
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
Anti LP40 anticuerpo, subclase IgG4
Eli Lilly and Company
2011 - EUCTR2010-022100-42-ES Hungary;Latvia;Spain;United Kingdom;
Anti-CD19-CAR-T cells
Shanghai GeneChem Co., Ltd.
2017 Phase 1 NCT03030976 China;
Anti-CD20 B cell depletion with Truxima
Leiden University Medical Center
2018 Phase 2;Phase 3 EUCTR2018-001392-21-NL Netherlands;
Anti-CD28dAb
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Anti-CD28dab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-IT Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Baxalta now part of Shire
2011 Phase 1 NCT01541670 Australia;Canada;Mexico;New Zealand;United States;
Anti-blood dendritic cell antigen 2
Biogen Idec Research Limited
2017 Phase 2 EUCTR2015-004359-32-PL Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2017 Phase 2 EUCTR2015-004359-32-BG Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Aspirin
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Tuen Mun Hospital
2006 Phase 4 NCT00371501 Hong Kong;
Aspirin and meloxicam
Vanderbilt University
2005 Phase 1 NCT00731302 United States;
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University
2021 Early Phase 1 NCT05030779 China;
Atacicept
EMD Serono
2014 Phase 2 NCT02070978 Argentina;Brazil;Bulgaria;Chile;Czechia;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2012 Phase 2 NCT01440231 United States;
2008 Phase 2/Phase 3 NCT00624338 Argentina;Australia;Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Merck Serono International
2008 - EUCTR2007-003698-13-BG Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-FR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003698-13-ES Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-GB Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-NL Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-LV Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-LT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-GR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States;
- - EUCTR2007-003698-13-DE Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
Merck Serono SA - Geneva
2008 - EUCTR2007-003698-13-AT Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Atacicept 75 milligram (mg)
EMD Serono
2013 Phase 2 NCT01972568 Argentina;Brazil;Bulgaria;Chile;Czech Republic;Czechia;Germany;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Atorvastatin
Buddhist Tzu Chi General Hospital
2007 Phase 2/Phase 3 NCT00432354 Taiwan;
Johns Hopkins University
2002 Phase 4 NCT00120887 United States;
NYU Langone Health
2002 Phase 2 NCT00412841 United States;
The Center for Rheumatic Disease, Allergy, & Immunology
2007 Phase 1/Phase 2 NCT00519363 United States;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INC-17011497 China;
Autologous CD34+HPC transplantation (HSCT)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Autologous EBV specific CTL infusion
Nantes University Hospital
2016 Phase 1/Phase 2 NCT02677688 France;
Autologous Hematopoietic Stem Cell Transplantation
European Society for Blood and Marrow Transplantation
2009 Phase 2/Phase 3 NCT05063513 France;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous hematopoietic stem cell transplantation
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Aviptadil
MONDOGEN AG
2008 - EUCTR2007-003621-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
MondoGEN AG
2009 - EUCTR2007-003621-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-003621-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Azathioprine
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
Hospital Universitari Vall d'Hebron Research Institute
2009 Phase 4 NCT01112215 Spain;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
BENLYSTA? (belimumab)
GlaxoSmithKline, S.A.
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
BENLYSTA™ (belimumab)
GlaxoSmithKline Research & Development Ltd
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
BI 705564
Boehringer Ingelheim
2019 Phase 1 NCT03771885 -
BIIB059
BIOGEN IDEC RESEARCH LIMITED
2021 Phase 3 EUCTR2020-005776-35-IT Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States;
Biogen
2021 Phase 3 NCT04961567 Argentina;Bulgaria;Colombia;Czechia;Hungary;Japan;United States;
2021 Phase 3 NCT04895241 Bulgaria;China;Poland;Spain;United States;
2016 Phase 2 NCT02847598 Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2014 Phase 1 NCT02106897 United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-005776-35-NL Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005776-35-HU Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005775-12-GR Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2021 Phase 3 EUCTR2020-005775-12-ES Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2017 Phase 2 EUCTR2015-004359-32-PL Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2017 Phase 2 EUCTR2015-004359-32-BG Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
BMS-188667
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
BMS-931699
Bristol-Myers Squibb
2014 Phase 2 NCT02265744 Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-IT Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-HU Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2014 Phase 2 EUCTR2014-002184-14-ES Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
BMS-986165
Bristol-Myers Squibb
2019 Phase 2 NCT03920267 Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 1 NCT03541564 United States;
2017 Phase 2 NCT03252587 Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States;
2017 Phase 1 NCT03262727 United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2018-003471-35-ES Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-RO Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-PL Argentina;Brazil;Canada;Colombia;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-HU Argentina;Brazil;Canada;Colombia;Hungary;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2017-001203-79-ES Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 2 EUCTR2017-001203-79-PL Argentina;Australia;Brazil;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 2 EUCTR2017-001203-79-DE Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
Bristol-Myers Squibb international Corporation
2017 Phase 2 EUCTR2017-001203-79-HU Argentina;Brazil;Bulgaria;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States;
BMS-986165 Capsule
Bristol-Myers Squibb
2017 Phase 1 NCT03254784 Netherlands;United States;
BMS-986165 Tablet
Bristol-Myers Squibb
2017 Phase 1 NCT03254784 Netherlands;United States;
BMS-986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986256
Ranganathan Usha
2022 Phase 2 JPRN-jRCT2011210069 Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;USA;United Kingdom;
BMS-986256 (Oral)
Bristol-Myers Squibb
2021 Phase 2 NCT04895696 Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
BMS-986256-06, TLR7/8 Antagonist
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
BMS986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
BOS161721
Boston Pharmaceuticals
2018 Phase 1/Phase 2 NCT03371251 Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
Boston Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2018-000305-23-HU Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
2019 Phase 2 EUCTR2018-000305-23-BG Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
BR-DIM
North Shore Long Island Jewish Health System
2016 Phase 1 NCT02483624 -
BT063
Biotest
2015 Phase 2 NCT02554019 Belarus;Georgia;Poland;Serbia;
Biotest AG
2015 Phase 2 EUCTR2014-005526-35-PL Belarus;Georgia;Poland;Serbia;
Baricinitib
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Baricitinib
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Eli Lilly Japan K.K.
2016 Phase 2 JPRN-JapicCTI-163359 -
- Phase 3 JPRN-JapicCTI-184095 -
Eli Lilly and Company
2019 Phase 3 NCT03843125 Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 NCT03616964 Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 NCT03616912 Australia;Austria;Belgium;Brazil;China;Croatia;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02708095 Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United States;
Belimumab
Affiliated Hospital of Guilin Medical College
2021 Phase 4 ChiCTR2100043138 China;
Biomedical Research Foundation, Academy of Athens
2020 - NCT04570306 -
First Affiliated Hospital Xi'an Jiaotong University
2022 Phase 4 NCT04893161 -
GlaxoSmithKline
2021 Phase 4 NCT04908865 -
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2017 Phase 1 NCT02880852 China;
2014 Phase 3 NCT02119156 China;Japan;Korea, Republic of;United States;
2012 Phase 3 NCT01597622 Japan;Korea, Republic of;
2012 Phase 2 NCT01649765 Argentina;Brazil;Canada;Italy;Japan;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - NCT01532310 United States;
2011 Phase 3 NCT01345253 China;Japan;Korea, Republic of;
2009 - NCT01914770 -
HUMAN GENOME SCIENCES INC
2009 Phase 3 EUCTR2007-007648-85-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences Inc.
2007 Phase 3 NCT00424476 Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Hong Kong;India;Korea, Republic of;Peru;Philippines;Romania;Russian Federation;Taiwan;
2006 Phase 3 NCT00410384 Austria;Belgium;Canada;Costa Rica;Czech Republic;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2003 Phase 2 NCT00071487 Canada;United States;
2002 Phase 1 NCT00657007 United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-SE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-DK Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences Inc., a GSK Company
2011 - NCT01858792 -
2008 Phase 3 NCT00724867 Canada;United States;
2008 Phase 3 NCT00712933 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Costa Rica;Czech Republic;Czechia;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2005 Phase 2 NCT00583362 Canada;United States;
Human Genome Sciences, Inc.
2012 - EUCTR2011-003814-18-ES Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
2012 Phase 3 EUCTR2011-003814-18-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Ishii Tomonori
2021 - JPRN-jRCTs021210042 Japan;
Oklahoma Medical Research Foundation
2014 Phase 4 NCT02270970 United States;
Peking Union Medical College Hospital
2021 Phase 4 NCT04956484 China;
Peking University People's Hospital
2022 Phase 3 NCT05262686 China;
RenJi Hospital
2021 Phase 4 NCT04515719 China;
University College London
2016 Phase 2 EUCTR2015-005543-14-GB United Kingdom;
Belimumab 10 mg/kg plus standard therapy
GlaxoSmithKline
2012 Phase 4 NCT01705977 Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;Indonesia;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Ukraine;United States;
Human Genome Sciences Inc., a GSK Company
2013 Phase 4 NCT01632241 Brazil;Colombia;France;South Africa;United Kingdom;United States;
Belimumab 100 mg SC
Human Genome Sciences Inc.
2008 Phase 2 NCT00732940 Mexico;United States;
Belimumab 200 mg SC
Human Genome Sciences Inc., a GSK Company
2011 Phase 3 NCT01484496 Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Belimumab 200 mg/mL
GlaxoSmithKline
2013 Phase 1 NCT01894360 United States;
Belimumab Injection
Leiden University Medical Center
2018 Phase 2 NCT03747159 Netherlands;
Belimumab Injection [Benlysta]
National University Hospital, Singapore
2020 Phase 4 NCT04447053 Singapore;
Belimumab autoinjector
GlaxoSmithKline
2014 Phase 2 NCT02124798 United States;
Belimumab for IV
GlaxoSmithKline
2019 Phase 1 NCT04136145 China;
Belimumab for SC
GlaxoSmithKline
2019 Phase 1 NCT04136145 China;
Belimumab or benlysta
Leiden University Medical Center
2018 Phase 2;Phase 3 EUCTR2018-001392-21-NL Netherlands;
Belimumab plus Early Vaccination
Human Genome Sciences Inc., a GSK Company
2012 Phase 4 NCT01597492 United States;
Belimumab plus Late Vaccination
Human Genome Sciences Inc., a GSK Company
2012 Phase 4 NCT01597492 United States;
Benazepril Pill
Northwell Health
2021 Phase 2 NCT04486118 United States;
Benlysta
GlaxoSmithKline
2018 - NCT03370263 Japan;
HUMAN GENOME SCIENCES INC
2012 - EUCTR2011-003814-18-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-SE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-DK Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc.
2012 - EUCTR2011-003814-18-ES Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
2012 Phase 3 EUCTR2011-003814-18-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Leiden University Medical Center
2014 Phase 2 EUCTR2014-000488-42-NL Netherlands;
Benlysta (Belimumab)
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
Benlysta (belimumab)
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2013 - EUCTR2011-000368-88-IT Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Spain;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Benlysta 400 mg powder for concentrate for solution for infusion
GlaxoSmithKline, LLC
2013 Phase 4 EUCTR2011-005667-25-PT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-LT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-HU Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-BG Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
HUMAN GENOME SCIENCES INC
2013 - EUCTR2011-005667-25-IT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;European Union;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Philippines;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2014 Phase 4 EUCTR2011-005667-25-PL Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-SK Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-EE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-RO Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-ES Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2013 Phase 3;Phase 4 EUCTR2011-005672-42-GB Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States;
Benlysta 400 mg powder for concentrate for solution for infusions
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Benlysta®
Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)
2021 Phase 4 EUCTR2021-001802-30-DE Germany;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Blisibimod
Anthera Pharmaceuticals
2016 Phase 3 NCT02514967 Georgia;
2015 Phase 3 NCT02074020 -
2013 Phase 3 NCT01395745 Belarus;Brazil;Colombia;Georgia;Guatemala;Hong Kong;India;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Singapore;Sri Lanka;Taiwan;Thailand;
Blood sample
University Hospital, Bordeaux
2021 - NCT04276701 France;Germany;Spain;
2020 - NCT04440566 France;
2018 - NCT03575156 France;
Bone densitometry
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Bortezomib
Charite University, Berlin, Germany
2014 Phase 2 NCT02102594 Germany;
Tohoku university hospital
2014 Phase 2 JPRN-UMIN000013508 Japan;
2013 Phase 2 JPRN-UMIN000012227 Japan;
Branebrutinib
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Brentuximab vedotin
Seagen Inc.
2015 Phase 2 NCT02533570 United States;
Brepocitinib
PFIZER INC
2021 Phase 2 EUCTR2018-004175-12-IT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Pfizer Inc.
2019 Phase 2 EUCTR2018-004175-12-PT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-PL Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-DE Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-BG Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Bronchoalveolar lavage (BAL fluid)
McGill University Health Centre/Research Institute of the McGill University Health Centre
2021 - NCT05007340 Canada;
Busulfan
New York Medical College
2007 Phase 1 NCT00684255 United States;
CC-220
Celgene
2017 Phase 2 NCT03161483 Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2014 Phase 2 NCT02185040 United States;
Celgene Corporation
2017 Phase 2 EUCTR2016-004574-17-HU Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-FR Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-ES Argentina;Belgium;Brazil;Canada;Colombia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-DE Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-BE Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
CD34+ Peripheral Blood Stem Cell Reinfusion
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
CDP3194
UCB Inc
2008 Phase 2 EUCTR2007-002589-37-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-002589-37-BE Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-LT Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 - EUCTR2007-002589-37-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
UCB Inc.
2012 Phase 3 EUCTR2010-020859-30-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-020859-30-EE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-018563-41-LT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2012 - EUCTR2010-018563-41-EE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 Phase 3 EUCTR2010-020859-30-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-018565-26-GB Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 Phase 3 EUCTR2010-018563-41-GB Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-020859-30-LT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020859-30-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-020859-30-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-018565-26-IT Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-HU Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-ES Germany;Hungary;Italy;Spain;United Kingdom;
2011 - EUCTR2010-018565-26-DE Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018563-41-IT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-018563-41-DE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-CZ Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BG Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
CDP7657
UCB Biopharma SPRL
2016 Phase 2 EUCTR2015-004457-40-PL Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-HU Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-ES Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-DE Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-BG Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003409-83-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003406-27-DK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003406-27-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-PT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003409-83-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-FR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
UCB Pharma
2013 Phase 1 NCT01764594 Belgium;Bulgaria;Germany;Poland;Romania;Russian Federation;Spain;
2010 Phase 1 NCT01093911 Belgium;Bulgaria;Germany;
CEP-33457
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
CFZ533
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharmaceuticals
2018 Phase 2 NCT03656562 Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
CNTO1275
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
COVID-19 vaccine
Paul R Fortin
2022 Phase 2/Phase 3 NCT05236491 -
CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)
Hanyang University Seoul Hospital
2019 Phase 2 NCT04835883 Korea, Republic of;
CSM allogéniques issues de cordons ombilicaux ( MTI-PP)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2017-001400-29-FR France;
CTLA4-IgG4m (RG2077)
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 1/Phase 2 NCT00094380 United States;
CTLA4Ig
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
Calcitriol
Chinese University of Hong Kong
2008 Phase 4 NCT00508898 Hong Kong;
Guilan University of Medical Sciences
2013 Phase 2 NCT01863641 Iran, Islamic Republic of;
Calcium
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Campath
New York Medical College
2007 Phase 1 NCT00684255 United States;
CellCept
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Cellcept
Cambridge University Hospitals NHS Foundation Trust
2005 Phase 2 EUCTR2005-002207-16-GB United Kingdom;
Cenerimod
IDORSIA PHARMACEUTICALS LTD
2019 Phase 2 EUCTR2018-001808-11-IT Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd
2020 Phase 2 EUCTR2018-001808-11-GR Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-PL Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-HU Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-FR Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-ES Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-DE Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-BG Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2018-001808-11-GB Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd.
2018 Phase 2 NCT03742037 Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 1/Phase 2 NCT02472795 Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States;
Yokoyama Yoshinari
2021 Phase 2 JPRN-jRCT2011210019 Japan;
Cervarix suspensie voor injectie
University Medical Center Utrecht
2009 - EUCTR2008-008169-36-NL Netherlands;
Cholecalciferol
Assistance Publique - Hôpitaux de Paris
2010 - NCT01413230 France;
Medical University of South Carolina
2011 Phase 2 NCT01911169 United States;
2006 Phase 1 NCT00418587 United States;
ROSA MARIA RODRIGUES PEREIRA
2012 - NCT01892748 Brazil;
Cholecalciferol and C. Xanthorrhiza
Saiful Anwar Hospital
2016 - NCT03155477 -
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Clopidogrel
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Combination Product: Belimumab
GlaxoSmithKline
2019 Phase 2 NCT04179032 Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
1997 Phase 4 NCT00392093 Mexico;
Continuation of azathioprine
Erasmus Medical Center
2007 Phase 3 NCT00504244 Netherlands;
Corn starch
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Corticosteroids
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Corticosteroids (prednisone or prednisolone)
Bristol-Myers Squibb
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
Creatine
University of Sao Paulo
2011 - NCT01217320 Brazil;
Crestor
Imperial College
2010 Phase 4 EUCTR2006-006214-16-GB United Kingdom;
Csa
Manuel Praga Terente
2010 - EUCTR2009-017273-38-ES Spain;
Cumulative corticosteroid exposure
GlaxoSmithKline
2012 - NCT01616472 -
Curcumin supplement
Loma Linda University
2019 Phase 2 NCT03953261 United States;
Cyclophosphamide
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
Institute of Rheumatology, Prague
2002 Phase 2 NCT00976300 Czech Republic;
Istituto Giannina Gaslini
2006 - EUCTR2005-003957-28-DK Denmark;Italy;
Johns Hopkins University
1997 - NCT00010400 United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 1/Phase 2 NCT00094380 United States;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Shanghai GeneChem Co., Ltd.
2017 Phase 1 NCT03030976 China;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Sun Yat-sen University
2010 - NCT01060410 China;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Cyclophosphamide-prednisone-azathioprine
Istituto Giannina Gaslini
2006 Phase 3 NCT00336414 Italy;
Cyclosporin A
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Cyclosporine A
Institute of Rheumatology, Prague
2002 Phase 2 NCT00976300 Czech Republic;
Cymbalta
Dr. Jesus Gutierrez Stone
2010 - NCT01269866 United States;
Cytarabine
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004643 -
DELTACORTENE*20CPR
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
DS-7011a
Daiichi Sankyo, Inc.
2022 Phase 1 NCT05203692 United States;
DZP
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 NCT04294667 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
Dapagliflozin
Dept. Rheumatology, Renji Hospital South Campus
2018 Phase 4 study ChiCTR1800015030 China;
Dapirolizumab pegol
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003409-83-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003406-27-DK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 NCT04976322 Argentina;Bulgaria;Canada;Hungary;Poland;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2019-003409-83-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003406-27-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-PT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003409-83-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-FR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
Dapirolizumab pegol (DZP)
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02804763 Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SPRL
2016 Phase 2 EUCTR2015-004457-40-PL Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-HU Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-ES Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-DE Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-BG Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Daratumumab
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
Daratumumab Injection
Charite University, Berlin, Germany
2021 Phase 2 NCT04810754 -
Darzalex
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
Dehydroepiandrosterone
National Center for Research Resources (NCRR)
1996 Phase 3 NCT00004662 -
1995 Phase 2 NCT00004665 -
1994 Phase 2/Phase 3 NCT00004795 -
UMC Utrecht
2000 Phase 2 NCT00391924 Netherlands;
Dehydroepiandrosterone (DHEA)
University of Michigan
2003 Phase 2/Phase 3 NCT00189124 United States;
Depletion of CD3/CD19 in an autologous stem cell transplant
Stephan Grupp MD PhD
2021 Phase 2 NCT05029336 United States;
Dihydroartemisinin tablet
Kunming Pharmaceuticals, Inc.
2018 Phase 2 NCT03396393 -
Dimethylfumarat
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Diphenhydramine
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Diphenhydramine hydrochloride
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Docosahexaenoic acid
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Doppler ultrasound
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Groupe Hospitalier Pitie-Salpetriere
2018 - NCT03480529 France;
E6742
Eisai Co., Ltd.
2022 Phase 1/Phase 2 NCT05278663 Japan;
EPA and DHA supplementation
University of Sao Paulo
2014 - NCT01956188 Brazil;
ERL080A
Novartis Pharma Services AG
2006 - EUCTR2005-003070-19-HU Hungary;
Edratide
TEVA Pharmaceutical Industries, Ltd.
2005 Phase 2 EUCTR2005-001391-12-GB Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2005-001391-12-ES Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-HU Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-DE Germany;Hungary;Italy;Spain;United Kingdom;
Teva Pharmaceutical Industries
2005 Phase 2 NCT00203151 United States;
Edratide Acetate
TEVA
2005 - EUCTR2005-001391-12-IT Germany;Hungary;Italy;Spain;United Kingdom;
Efavaleukin alfa
Hama Yoriko
2021 Phase 2 JPRN-jRCT2041210076 Greece,;Japan;Korea, Republic of;Poland;Spain;Turkey;United States;
Eicosapentaenoic acid
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Elsubrutinib
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie
2020 Phase 2 NCT04451772 Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03978520 Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
Emapalumab
Swedish Orphan Biovitrum
2021 Phase 3 NCT05001737 -
Enteric-Coated Mycophenolate Sodium
Hospital Universitari Vall d'Hebron Research Institute
2009 Phase 4 NCT01112215 Spain;
Epatuzumab
IMMUNOMEDICS
2005 - EUCTR2005-000706-31-IT Germany;Italy;Spain;United Kingdom;
Epratuzumab
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Inc
2008 Phase 2 EUCTR2007-002589-37-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-002589-37-BE Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-LT Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 - EUCTR2007-002589-37-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
UCB Inc.
2012 - EUCTR2010-020859-30-EE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-018563-41-LT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2012 - EUCTR2010-018563-41-EE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 Phase 3 EUCTR2010-020859-30-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-018565-26-GB Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 Phase 3 EUCTR2010-018563-41-GB Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-020859-30-LT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020859-30-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-020859-30-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-018565-26-HU Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-ES Germany;Hungary;Italy;Spain;United Kingdom;
2011 - EUCTR2010-018565-26-DE Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018563-41-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-018563-41-DE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-CZ Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BG Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
UCB Pharma
2012 Phase 2 NCT01534403 Japan;
2011 Phase 3 NCT01408576 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 1/Phase 2 NCT01449071 Japan;
2010 Phase 3 NCT01262365 Australia;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Estonia;France;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
2010 Phase 3 NCT01261793 Brazil;Canada;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2008 Phase 2 NCT00660881 Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States;
2008 Phase 2 NCT00624351 Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States;
2007 Phase 3 NCT00382837 Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;United States;
2006 Phase 2 NCT00383513 Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2005 Phase 3 NCT00383214 Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2005 Phase 3 NCT00111306 Belgium;Hungary;Netherlands;Spain;United Kingdom;United States;
2005 Phase 2 NCT00113971 United States;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
Epratuzumab iv
UCB Biopharma S.P.R.L.
2014 Phase 1 NCT02306629 United Kingdom;
Epratuzumab sc
UCB Biopharma S.P.R.L.
2014 Phase 1 NCT02306629 United Kingdom;
Ethinyl estradiol
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Ethylhydrogenfumarat, Calciumsalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Ethylhydrogenfumarat, Magnesiumsalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Ethylhydrogenfumarat, Zinksalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Evobrutinib
Merck KGaA
2017 Phase 2 EUCTR2016-002950-19-PL Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
Extended release dipyridamole 200mg/aspirin
Oklahoma Medical Research Foundation
2013 - NCT01781611 United States;
Ezetimibe+Simvastatin Drug Combination
Peking Union Medical College Hospital
2015 Phase 0 NCT02548936 China;
Fan beam CT scan
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Johns Hopkins University
1997 - NCT00010400 United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Flash glucose monitoring system
RenJi Hospital
2017 - NCT03296995 China;
Flow-mediated dilation of the brachial artery
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Fludarabine
New York Medical College
2007 Phase 1 NCT00684255 United States;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Fludarabine phosphate
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Fluzone
University of Alabama at Birmingham
2007 - NCT00611611 United States;
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Forigerimod
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
Fostamatinib Disodium (R935788)
Rigel Pharmaceuticals
2008 Phase 2 NCT00752999 -
Fumaderm®
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Fumaderm® initial
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
GC+HCQ
Peking Union Medical College Hospital
2016 - NCT02842814 China;
GDC-0853
Genentech, Inc.
2018 Phase 2 NCT03407482 Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 NCT02908100 Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;Thailand;United Kingdom;United States;
GDC-0853 RO7010939
Genentech, Inc.
2018 Phase 2 EUCTR2017-001764-37-PT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-PT Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-ES Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001039-11-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
Roche Farma, S.A por delegación de Genentech, Inc.
2017 Phase 2 EUCTR2017-001764-37-ES Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
GL701
Genelabs Technologies
1998 Phase 3 NCT00037128 United States;
GLPG3970 film-coated tablet
Galapagos NV
2020 Phase 1 NCT04700267 Bulgaria;Moldova, Republic of;Poland;Spain;Ukraine;
GSK1550188
GlaxoSmithKline Research & Development Ltd
2020 Phase 2 EUCTR2018-004645-16-NL Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2019 Phase 2 EUCTR2018-004645-16-DE Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2019 Phase 2 EUCTR2018-004645-16-ES Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GSK1550188 1mg/kg or
GlaxoSmithKline
2010 Phase 1 NCT01381536 Japan;
GSK1550188 IV
GlaxoSmithKline
2011 Phase 1 NCT01516450 Japan;
GSK1550188 SC
GlaxoSmithKline
2011 Phase 1 NCT01516450 Japan;
GSK2586184
GlaxoSmithKline
2013 Phase 2 NCT01777256 Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-001645-41-SE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-PL Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-DE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-CZ Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 Phase 2 EUCTR2012-001645-41-EE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden;
2012 - EUCTR2012-001645-41-HU Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 - EUCTR2012-001645-41-GR Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GlaxoSmithKline, S.A.
2012 - EUCTR2012-001645-41-ES Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GSK2586184 800mg single and repeat dose
GlaxoSmithKline
2012 Phase 1 NCT01687309 Belgium;
GSK2586184 new formulation
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
GSK2586184 standard formulation
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Gardasil
University of Chicago
2008 - NCT00786409 United States;
Wayne State University
2013 Phase 1 NCT01741012 United States;
Gazyvaro
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-005760-57-IT Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-005760-57-PL Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-005760-57-ES Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Gold
The Affiliated Drum Tower Hospital of Nanjing University Medical School
2021 Phase 0 ChiCTR2100048082 China;
Tianjin Children's Hospital
2020 - ChiCTR2000038519 China;
Group A SLE prospective study
Oklahoma Medical Research Foundation
2009 Phase 1/Phase 2 NCT00987831 United States;
Growth colony stimulating factor (G-CSF)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
H.P. Acthar Gel
Fiechtner, Justus J., M.D., P.C.
2012 Phase 4 NCT01769937 United States;
HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM
BIOGEN IDEC RESEARCH LIMITED
2021 Phase 3 EUCTR2020-005776-35-IT Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 - NCT04907175 United States;
HGS1006
HUMAN GENOME SCIENCES INC
2009 Phase 3 EUCTR2007-007648-85-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc
2009 Phase 3 EUCTR2007-007648-85-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc.
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
HLL2
UCB Inc
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
HLL2 (Epratuzumab)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2001 Phase 1 NCT00011908 United States;
HLL2 (trivial name or chemical description)
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
HLL2,IMMU-103
IMMUNOMEDICS
2005 - EUCTR2005-000706-31-IT Germany;Italy;Spain;United Kingdom;
HPV prophylactic vaccine Gardasil
University Hospital, Bordeaux
2012 Phase 2 NCT01687192 France;
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278538 United States;
High Dietary Sodium
Vanderbilt University
2018 - NCT02525835 United States;
High Dose Mesenchymal Stem Cells (MSCs)
Medical University of South Carolina
2018 Phase 2 NCT02633163 United States;
Hiomega-3 supplement of Naturalis® company -
Federal University of Minas Gerais
2009 - NCT02524795 -
HrIL-2 active
Peking University People's Hospital
2015 Phase 2 NCT02465580 China;
Human papillomavirus vaccination (Gardasil)
Tuen Mun Hospital
2009 Phase 4 NCT00911521 China;
Human umbilical cord derived MSC transplantation for SLE
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2012 Phase 1/Phase 2 NCT01741857 China;
Humanised IgG1 monoclonal antibody against blood dendritic cell antigen 2
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-005776-35-NL Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005776-35-HU Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005775-12-GR Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2021 Phase 3 EUCTR2020-005775-12-ES Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
Hydroxychloroquine
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Department of Internal Medicine, Teikyo University School of Medicine
2014 - JPRN-UMIN000012478 Japan;
Ishii Tomonori
2021 - JPRN-jRCTs021210042 Japan;
Milton S. Hershey Medical Center
2017 Phase 2 NCT03030118 United States;
Nanjing University of Chinese Medicine Affiliated Hospital
2019 Phase 1 study ChiCTR1800020286 China;
2019 Phase 1 ChiCTR1900022934 China;
Renji Hospital, Shanghai JiaoTong University School of Medicine
2012 - ChiCTR-TRC-12002419 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Hydroxychloroquine (Z0188)
Sanofi
2012 Phase 3 NCT01551069 Japan;
Hydroxychloroquine or Chloroquine
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01946880 United States;
Hydroxychloroquine reduced
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
ICI 182,780 (Faslodex)
The Center for Rheumatic Disease, Allergy, & Immunology
2004 Phase 2 NCT00417430 United States;
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
2020 Phase 1/Phase 2 NCT04305197 China;
Innocare Pharma Australia Pty Ltd
2017 Phase 1 NCT03189017 Australia;
IFN-K
NEOVACS
2015 Phase 2 EUCTR2015-001341-86-IT Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
Neovacs
2010 Phase 1/Phase 2 NCT01058343 Belgium;Bulgaria;Croatia;France;Germany;Romania;Spain;Switzerland;
Neovacs S.A.
2017 Phase 2 EUCTR2015-001341-86-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2017 Phase 2 EUCTR2015-001341-86-BG Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-DE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-BE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
Neovas S.A.
2015 Phase 2 EUCTR2015-001341-86-HR Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States;
IFN-Kinoid
NEOVACS
2015 Phase 2 EUCTR2015-001341-86-IT Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
IFN-Kinoid Drug Substance
Neovacs S.A.
2017 Phase 2 EUCTR2015-001341-86-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2017 Phase 2 EUCTR2015-001341-86-BG Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-DE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-BE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
Neovas S.A.
2015 Phase 2 EUCTR2015-001341-86-HR Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States;
IFN-a 2b Kinoid Drug Substance
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
IFN-a2b Kinoid
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
IFNa-Kinoid
Neovacs
2015 Phase 2 NCT02665364 Argentina;Belgium;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Switzerland;Taiwan;Thailand;Tunisia;United States;
IL-2
The First Hospital of Jilin University
2020 - NCT04397107 China;
the Second Hospital of Shanxi Medical University
2016 - ChiCTR-IPR-16009451 China;
IL-6R nanobody
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-PT Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-ES Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
ILT-101
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-IT Austria;Bulgaria;France;Italy;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
Iltoo Pharma
2017 Phase 2 NCT02955615 Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
IMMU-103
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
IMMUNOGLOBULIN G
Boston Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2018-000305-23-HU Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
2019 Phase 2 EUCTR2018-000305-23-BG Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
INTERLEUKIN-2
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
IPP - 201101
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
IPP-201101
IMMUPHARMA
2016 Phase 3 EUCTR2015-003341-25-IT France;Germany;Hungary;Italy;United Kingdom;
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
ImmuPharma
2018 Phase 3 NCT03427151 Czechia;France;Germany;Hungary;Mauritius;Poland;Puerto Rico;United States;
2018 Phase 3 EUCTR2017-004060-35-HU Hungary;Mauritius;United States;
2015 Phase 3 NCT02504645 Czech Republic;Czechia;France;Germany;Hungary;Italy;Mauritius;Poland;Puerto Rico;United States;
ImmuPharma SA
2016 Phase 3 EUCTR2015-003341-25-HU France;Germany;Hungary;United States;
2016 Phase 3 EUCTR2015-003341-25-GB France;Germany;Hungary;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003341-25-FR France;Germany;Hungary;United States;
2016 Phase 3 EUCTR2015-003341-25-DE France;Germany;Hungary;United Kingdom;United States;
IPP-201101, P140
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
IS (B cell depletion therapy)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MMF or MPA)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MTX)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Ianalumab
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Ibandronate+alfacalcidol+calcium
Chinese University of Hong Kong
2007 Phase 4 NCT00668330 China;
Immune ablation and hematopoietic stem cell support.
Richard Burt, MD
2002 Phase 2 NCT00271934 United States;
Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer
Astrazeneca AB
2017 Phase 2 EUCTR2016-003246-93-PL Hungary;Korea, Republic of;Poland;United States;
Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
Individualized dose of rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 4 NCT04127747 China;
Infliximab
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
Medical University of Vienna
2006 Phase 2/Phase 3 NCT00368264 Austria;Germany;Netherlands;
Influenz virus surface antigens
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
Influvac
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
Intravenous immunoglobulin
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Iscalimab
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Itolizumab [Bmab 600]
Equillium
2019 Phase 1 NCT04128579 India;Poland;United States;
JBT-101
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 2 NCT03093402 United States;
JNJ-54767414
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
JNJ-55920839
Janssen Research & Development, LLC
2015 Phase 1 NCT02609789 Belgium;Moldova, Republic of;Poland;Romania;Spain;Taiwan;United States;
JNJ-56022473
Janssen Research & Development, LLC
2017 Phase 1 NCT02920424 Germany;
JNJ-80202135
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
KPG-818
Kangpu Biopharmaceuticals, Ltd.
2019 Phase 1 NCT03949426 United States;
KPG-818 dose
Kangpu Biopharmaceuticals, Ltd.
2021 Phase 1/Phase 2 NCT04643067 United States;
KZR-616
Kezar Life Sciences, Inc.
2018 Phase 1/Phase 2 NCT03393013 Australia;Colombia;Mexico;Peru;Poland;Russian Federation;Ukraine;United States;
L04AA26
GlaxoSmithKline, LLC
2013 Phase 4 EUCTR2011-005667-25-PT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-LT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-HU Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-BG Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2014 Phase 4 EUCTR2011-005667-25-PL Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-SK Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-EE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-RO Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-ES Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2013 Phase 3;Phase 4 EUCTR2011-005672-42-GB Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States;
LA294
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
LABP-104
Landos Biopharma Inc.
2021 Phase 1 NCT05019950 Australia;
LJP 394
LA JOLLA PHARMACEUTICAL COMPANY
2008 - EUCTR2006-000674-73-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
La Jolla Pharmaceutical Company
2008 - EUCTR2006-000674-73-PT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-ES Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-DE Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-CZ Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-BG Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2006 Phase 3 EUCTR2006-000674-73-SK Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain;
2006 - EUCTR2006-000674-73-HU Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
LJP394
AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
2009 - EUCTR2008-004852-62-IT Italy;
LY2127399
ELI LILLY
2011 - EUCTR2010-022099-29-IT Austria;Bulgaria;Germany;Italy;
ELI LILLY AND COMPANY
2013 - EUCTR2010-022101-18-IT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 NCT01488708 United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01205438 Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-ES Hungary;Latvia;Spain;United Kingdom;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2010 Phase 3 NCT01196091 Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, The Former Yugoslav Republic of;Peru;Philippines;Poland;Puerto Rico;Singapore;Thailand;Turkey;Ukraine;United States;
LY3009104
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-184095 -
Eli Lilly and Company
2020 Phase 3 EUCTR2017-005028-11-NL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-RO Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-PL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-GB Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-ES Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-NL Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-HR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GB Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-ES Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 EUCTR2017-005026-37-HU Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-CZ Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-BE Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-AT Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-PL Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-FR Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-AT Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States;
Lilly S.A.
2016 Phase 2 EUCTR2015-004404-35-ES Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States;
LY3361237
Eli Lilly and Company
2022 Phase 2 NCT05123586 Argentina;Czechia;Mexico;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
2019 Phase 1 NCT03933943 United States;
LY3471851
Eli Lilly & Company
2021 Phase 2 EUCTR2019-003323-38-DE Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-PL Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-HU Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-GB Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 2 NCT04433585 Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 1 NCT03556007 United States;
Laquinimod
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
Teva Pharmaceutical Industries
2010 Phase 2 NCT01085084 Canada;United States;
Leflunomide
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Sanofi
2003 Phase 2 NCT00637819 Hong Kong;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Lenalidomide
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900025376 China;
Leukapheresis
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Levothyroxine
Johns Hopkins University
2011 Phase 4 NCT01276782 United States;
Lisinopril Pills
Northwell Health
2021 Phase 2 NCT04486118 United States;
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)
Bristol-Myers Squibb
2017 Phase 1 NCT03262727 United States;
Low Dietary Sodium
Vanderbilt University
2018 - NCT02525835 United States;
Low Dose Mesenchymal Stem Cells (MSCs)
Medical University of South Carolina
2018 Phase 2 NCT02633163 United States;
2017 Phase 1 NCT03171194 United States;
Low-dose Aldesleukin (Proleukin®)
Onur Boyman, MD
2018 Phase 2 NCT03312335 Switzerland;
Lulizumab pegol
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb K.K.
2015 Phase 2 JPRN-JapicCTI-153077 Japan, Asia except Japan, North America, South America, Europe;
Lupuzor
Cephalon
2010 Phase 3 NCT01240694 Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States;
2010 Phase 2 NCT01135459 Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States;
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
LymphoStat-B
Human Genome Sciences, Inc
2009 Phase 3 EUCTR2007-007648-85-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc.
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
LymphoStat-B TM
Human Genome Sciences, Inc.
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
LymphoStat-B®, monoclonal anti-BLyS, LSB, BENLYSTA®
GlaxoSmithKline Research & Development Ltd
2020 Phase 2 EUCTR2018-004645-16-NL Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2019 Phase 2 EUCTR2018-004645-16-DE Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
GlaxoSmithKline, S.A.
2019 Phase 2 EUCTR2018-004645-16-ES Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
M281
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
M2951
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02975336 Argentina;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
Merck KGaA
2017 Phase 2 EUCTR2016-002950-19-PL Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
M2951 (Other Name: Evobrutinib)
Merck Biopharma Co., Ltd
2017 Phase 2 JPRN-JapicCTI-183957 Japan, Asia except Japan, North America, South America, Europe, Africa;
M5049
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2020 Phase 1 NCT04647708 Bulgaria;Germany;Moldova, Republic of;Spain;Ukraine;
M5049 high dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
M5049 low dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
M5049 medium dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
MEDI 545
MedImmune LLC
2007 Phase 1 NCT00482989 Argentina;Brazil;Canada;Chile;United States;
2006 Phase 1 NCT00299819 Canada;United States;
MEDI-545
ASTRAZENECA
2011 - EUCTR2010-024069-30-IT Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States;
AstraZeneca AB
2012 - EUCTR2010-024069-30-BG Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 Phase 2 EUCTR2010-024069-30-GB Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-NL Argentina;Brazil;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-ES Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-DE Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
- - EUCTR2010-024069-30-HU Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
MedImmune LLC
2008 Phase 2 NCT00657189 United States;
2006 Phase 1 NCT00299819 Canada;United States;
MEDI-545 600
AstraZeneca
2009 Phase 2 NCT01031836 Japan;
MEDI-546
AstraZeneca
2021 Phase 3 EUCTR2020-004529-22-HU Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004529-22-BG Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 NCT01559090 Japan;
AstraZeneca AB
2017 Phase 3 EUCTR2016-000625-39-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Astrazeneca AB
2016 Phase 2 EUCTR2016-003246-93-HU Hungary;Korea, Republic of;Poland;United States;
MedImmune, LLC
2013 Phase 2 EUCTR2011-004296-36-BG Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 - EUCTR2011-004296-36-HU Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2012 - EUCTR2011-004296-36-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Israel;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
MEDI-570
MedImmune LLC
2010 Phase 1 NCT01127321 Canada;Mexico;Peru;South Africa;United States;
MHS552
Novartis Pharmaceuticals
2022 Phase 1 NCT05203419 -
MMF
Atsumi Tatsuya
2020 Phase 4 JPRN-jRCTs011190011 Japan;
MRA 003 US
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 Phase 1 NCT00046774 United States;
MRI, Venipuncture
NYU Langone Health
2002 Phase 2 NCT00412841 United States;
MRNA COVD19 vaccine
Mayo Clinic
2021 Early Phase 1 NCT04839315 United States;
MSC treatment
Universidad de los Andes, Chile
2019 Phase 2 NCT03917797 Chile;
MSC2364447C
EMD Serono Research & Development Institute, Inc.
2015 Phase 1 NCT02537028 Bulgaria;United States;
MT-1303 High dose
Mitsubishi Tanabe Pharma Corporation
2015 Phase 1 NCT02307643 Japan;
MT-1303 Low dose
Mitsubishi Tanabe Pharma Corporation
2015 Phase 1 NCT02307643 Japan;
MTX
Zhejinag University of f Chinese Medicine
2020 Phase 0 ChiCTR2000030247 China;
MYFORTIC*50CPR RIV
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
MabThera (Rituximab)
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
Medi-546
AstraZeneca
2021 Phase 3 NCT04877691 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
2014 Phase 2 EUCTR2012-004619-30-BG Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-HU Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
Medroxyprogesterone
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Melatonin
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900020803 China;
Memantine
Johns Hopkins University
2006 - NCT00181298 United States;
Vanderbilt University Medical Center
2018 Phase 2 NCT03527472 United States;
Mesenchymal stem cells
Assistance Publique - Hôpitaux de Paris
2019 Phase 1/Phase 2 NCT03562065 France;
Hebei Medical University
2017 Early Phase 1 NCT03219801 China;
Mesna
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Metformin
RenJi Hospital
2016 Phase 4 NCT02741960 China;
Renji Hospital, Shanghai JiaoTong University School of Medicine
2012 - ChiCTR-TRC-12002419 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INC-17011497 China;
Methotrexate
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Methotrexate and folic acid
University Health Network, Toronto
1995 Phase 3 NCT00470522 Canada;
Methyl prednisolone
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
Methylprednisolone
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
2006 Phase 3 NCT00381810 United States;
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Oklahoma Medical Research Foundation
2017 Phase 2 NCT03355482 United States;
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Methylprednisolone sodium succinate
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Milatuzumab
Gilead Sciences
2007 Phase 1 NCT01845740 United States;
Milnacipran
Loma Linda University
2011 Phase 4 NCT01359826 United States;
Mizoribine
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
Modafinil
Hospital for Special Surgery, New York
2006 - NCT00297284 United States;
Moderna mRNA-1273
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Mosunetuzumab
Hoffmann-La Roche
2022 Phase 1 NCT05155345 Moldova, Republic of;Ukraine;United States;
Moxifloxacin
Bristol-Myers Squibb
2018 Phase 1 NCT03541564 United States;
Multivitamin
Chinese University of Hong Kong
2008 Phase 4 NCT00508898 Hong Kong;
Mycophenolate mofetil
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Guy's and St Thomas' NHS Foundation Trust
2006 Phase 4 NCT01101802 United Kingdom;
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Oklahoma Medical Research Foundation
2006 Phase 1/Phase 2 NCT00594932 United States;
Ruijin Hospital
2018 - ChiCTR1800017540 China;
The University of Hong Kong
2015 - JPRN-UMIN000025328 Japan,Asia(except Japan);
Mycophenolate mofetil (MMF)
Bristol-Myers Squibb
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
Mycophenolate motetil
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Mycophenolic acid
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Myfortic
Cambridge University Hospitals NHS Foundation Trust
2005 Phase 2 EUCTR2005-002207-16-GB United Kingdom;
Novartis Pharma Services AG
2006 - EUCTR2005-003070-19-HU Hungary;
N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-001645-41-SE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-PL Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-DE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-CZ Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 Phase 2 EUCTR2012-001645-41-EE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden;
2012 - EUCTR2012-001645-41-HU Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 - EUCTR2012-001645-41-GR Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GlaxoSmithKline, S.A.
2012 - EUCTR2012-001645-41-ES Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
N-acetylcysteine
State University of New York - Upstate Medical University
2021 Phase 2 NCT00775476 United States;
NNC 0151-0000-0000
Novo Nordisk A/S
2009 Phase 1 NCT01018238 United States;
2008 Phase 1 NCT02151409 Netherlands;
NNC0114-0006
Novo Nordisk A/S
2012 Phase 1 NCT01689025 Hungary;Poland;Serbia;United States;
NON APPLICABILE
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001567-25-IT Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
NOX-E36
NOXXON Pharma AG
2009 Phase 1 NCT00976729 United Kingdom;
Nelfinavir
Northwell Health
2014 Phase 2 NCT02066311 United States;
Nicotinamide
Second Xiangya Hospital of Central South University
2017 Phase 2 NCT03260166 China;
Nipocalimab
Janssen Research & Development, LLC
2021 Phase 2 NCT04882878 Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Numaguchi Hirotaka
2022 Phase 2 JPRN-jRCT2041210058 Bulgaria;Colombia;Germany;Hungary;Japan;Poland;South Africa;Spain;Taiwan, Province Of China;Ukraine;United States OfAmerica;
Nivolumab
Alliance Foundation Trials, LLC.
2019 Phase 1 NCT03656627 United States;
National Cancer Institute (NCI)
2019 Phase 1 NCT03816345 Canada;United States;
Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Norethindrone
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Normal Saline
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
ORENCIA 125 mg solution for injection in pre-filled syringe
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Obinutuzumab
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Obinutuzumab administration
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Ocrelizumab
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
2007 Phase 3 NCT00539838 United States;
Olumiant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 3 EUCTR2017-005028-11-NL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-RO Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-PL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-GB Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-ES Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-NL Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-HR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GB Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-ES Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 EUCTR2017-005026-37-HU Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-CZ Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-BE Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-AT Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Olumiant - EU/1/16/1170/001-008
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Olumiant - EU/1/16/1170/009-016
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Omacor
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Omega-3
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Oral Prednisone
University of Pisa
2019 - NCT03804723 -
Oral prednisolone
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
Orencia
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Ortho-Novum 777
New York University School of Medicine
1997 Phase 3 NCT00000420 United States;
Oxygen
Guangdong Provincial Hospital of Chinese Medicine
2017 - ChiCTR-IOR-17012802 China;
Ozone
Guangdong Provincial Hospital of Chinese Medicine
2017 - ChiCTR-IOR-17012802 China;
P 140
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
PAH
Guangdong Provincial People's Hospital
2020 - ChiCTR2000030342 China;
PF-04236921
Pfizer
2011 Phase 2 NCT01405196 Argentina;Chile;Colombia;Germany;Hungary;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Poland;Puerto Rico;Romania;Taiwan;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 - EUCTR2011-000420-15-HU Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States;
2012 - EUCTR2011-000420-15-DE Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States;
PF-06700841
Pfizer
2019 Phase 2 NCT03845517 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
PF-06700841-15
PFIZER INC
2021 Phase 2 EUCTR2018-004175-12-IT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Pfizer Inc.
2019 Phase 2 EUCTR2018-004175-12-PT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-PL Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-HU Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-GB Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-ES Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-DE Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-CZ Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-BG Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
PF-06835375
Pfizer
2017 Phase 1 NCT03334851 Puerto Rico;United States;
Paquinimod
Active Biotech Research AB
2009 - EUCTR2009-011245-55-SE Denmark;Sweden;
2009 - EUCTR2009-011245-55-DK Denmark;Sweden;
Paquinimod (ABR-215757)
Active Biotech AB
2009 Phase 2 NCT00997100 Denmark;Sweden;
Phosphate-buffered saline
La Jolla Pharmaceutical Company
2004 Phase 3 NCT00089804 Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States;
Pioglitazone
National Heart Institute, Mexico
2007 Phase 4 NCT01322308 -
Pitavastatin
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Placebo
AstraZeneca
2017 Phase 3 JPRN-JapicCTI-173544 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2016 Phase 3 JPRN-JapicCTI-153064 Japan, Asia except Japan, North America, South America, Europe, Africa;
Eli Lilly Japan K.K.
2016 Phase 2 JPRN-JapicCTI-163359 -
- Phase 3 JPRN-JapicCTI-184095 -
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183973 Japan, Asia except Japan, North America, South America, Europe, Africa;
Merck Biopharma Co., Ltd
2017 Phase 2 JPRN-JapicCTI-183957 Japan, Asia except Japan, North America, South America, Europe, Africa;
Plaquenil
Christine Bengtsson
2015 Phase 2 EUCTR2014-005418-45-SE Sweden;
Plasmapheresis
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Pneumovax
University of Alabama at Birmingham
2007 - NCT00611611 United States;
Polymorphism Analysis
Sun Yat-sen University
2010 - NCT01060410 China;
Pooled mesenchymal stem cell
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2019 Phase 1/Phase 2 NCT04184258 Belarus;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Prasterone (GL701)
Genelabs Technologies
2003 Phase 3 NCT00082511 Mexico;United States;
2002 Phase 3 NCT00053560 Mexico;United States;
Pravastatin
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Prednisolone
Atsumi Tatsuya
2020 Phase 4 JPRN-jRCTs011190011 Japan;
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Zenyaku Kogyo Co., Ltd.
2007 - JPRN-UMIN000000639 Japan;
Prednisolone/Prednisone
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
Prednisone
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 4 EUCTR2017-002050-36-FR France;
Ampel BioSolutions, LLC
2017 Phase 4 NCT03098823 United States;
Bristol-Myers Squibb
2005 Phase 2 NCT00119678 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01946880 United States;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
New York University School of Medicine
1997 Phase 2 NCT00000421 United States;
Peking University First Hospital
2021 Phase 0 ChiCTR2100048635 China;
Ruijin Hospital
2018 - ChiCTR1800017540 China;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Zhejinag University of Chinese Medicine
2008 Phase 3 study ChiCTR-TRC-12001935 China;
Prednisone acetate
Nanjing University of Chinese Medicine Affiliated Hospital
2019 Phase 1 study ChiCTR1800020286 China;
2019 Phase 1 ChiCTR1900022934 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Prednisone discontinuation
Groupe Hospitalier Pitie-Salpetriere
2014 Phase 3 NCT02558517 France;
Premarin and Provera
New York University School of Medicine
1996 Phase 3 NCT00000419 United States;
Prevenar® and Pneumo23®
Assistance Publique - Hôpitaux de Paris
2008 Phase 2/Phase 3 NCT00611663 France;
Proleukin
Charité - Universitätsmedizin Berlin
2014 Phase 1;Phase 2 EUCTR2013-001599-40-DE Germany;
Quinipril
University Health Network, Toronto
2002 Phase 4 NCT00188188 Canada;
R-salbutamol sulphate
Astion Pharma A/S
2007 - EUCTR2007-004635-29-SE Denmark;Spain;Sweden;
2007 - EUCTR2007-004635-29-DK Denmark;Spain;Sweden;
R932333
Rigel Pharmaceuticals
2012 Phase 2 NCT01597050 Canada;United States;
RANKL/OPG ratio
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
RAYOS
Ampel BioSolutions, LLC
2017 Phase 4 NCT03098823 United States;
RC18 160 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RemeGen Co., Ltd.
2019 Phase 3 NCT04082416 China;
RC18 240 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RC18 80 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RECOMBINANT FACTOR FC FUSION PROTEIN
AMGEN INC.
2021 Phase 2 EUCTR2020-003509-72-IT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-002564-40-DE France;Germany;Poland;United States;
Amgen Inc.
2021 Phase 2 EUCTR2020-003509-72-PL Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-GR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-FR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-ES Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-BG Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-AT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
RO 496-4913
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
RO7010939/F13
Genentech, Inc.
2018 Phase 2 EUCTR2017-001764-37-PT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-PT Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-ES Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001039-11-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
Roche Farma, S.A por delegación de Genentech, Inc.
2017 Phase 2 EUCTR2017-001764-37-ES Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
ROSUVASTATIN CALCIUM
Imperial College
2010 Phase 4 EUCTR2006-006214-16-GB United Kingdom;
RSLV-132
Resolve Therapeutics
2016 Phase 2 NCT02660944 United States;
2014 Phase 1 NCT02194400 United States;
Rabbit anti-thymocyte globulin
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Rabbit antithymocyte globulin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Ramipril
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Federal University of São Paulo
2011 Phase 2/Phase 3 NCT03979976 Brazil;
Rapamycin
State University of New York - Upstate Medical University
2008 Phase 2 NCT00779194 United States;
the Second Hospital of Shanxi Medical University
2016 - ChiCTR-IPR-16009451 China;
Raptiva
Universitätskrankenhaus Schleswig-Holstein
2009 - EUCTR2008-003833-25-DE Germany;
Recombinant zoster vaccine
RenJi Hospital
2021 - NCT04516408 China;
Reduced Intensity Allogeneic Transplant
New York Medical College
2007 Phase 1 NCT00684255 United States;
Remicade
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
RhuMAb 2H7
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
RhuMAb IFNalpha
Genentech, Inc.
2007 Phase 1 NCT00541749 United States;
Rigerimod
Cephalon, Inc.
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
Rituxan (rituximab)
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Rituximab
Assiut University
2021 Phase 3 NCT05057481 Egypt;
Cambridge University Hospitals NHS Foundation Trust
2002 Phase 2 NCT00293072 United Kingdom;
Chinese University of Hong Kong
2006 Phase 2 NCT00556192 China;
European Society for Blood and Marrow Transplantation
2009 Phase 2/Phase 3 NCT05063513 France;
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
2001 Phase 1/Phase 2 NCT00036491 United States;
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
Zenyaku Kogyo Co., Ltd.
2007 - JPRN-UMIN000000763 Japan;
Rivaroxaban
University College London
2019 Phase 2;Phase 3 EUCTR2018-001735-49-GB United Kingdom;
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
University College, London
2020 Phase 2/Phase 3 NCT03684564 -
Ro 106-1443
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Rontalizumab
Chugai Pharmaceutical Co., Ltd.
2012 Phase 1 JPRN-JapicCTI-121864 -
Genentech, Inc.
2009 Phase 2 NCT00962832 Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom;United States;
Rosuvastatin
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Imperial College London
2010 Phase 2 NCT01170585 United Kingdom;
Ramathibodi Hospital
2008 Phase 4 NCT00866229 Thailand;
Tuen Mun Hospital
2006 Phase 4 NCT00371501 Hong Kong;
Royal jelly
Faculty of medicine, University of Assiut, Assiut 71516, Egypt.
2015 - JPRN-UMIN000020859 Africa;
Rozibafusp Alfa
Amgen
2020 Phase 2 NCT04058028 Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United States;
SAR113244
Sanofi
2016 Phase 1 NCT02331810 -
2014 Phase 1 NCT02321709 Germany;
SAR441344
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001567-25-IT Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
Sanofi-Aventis Recherche et Développement
2021 Phase 2 EUCTR2021-001567-25-ES Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2021-001567-25-DE Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
SAR441344 IV
Sanofi
2021 Phase 2 NCT05039840 United States;
SAR441344 SC
Sanofi
2021 Phase 2 NCT05039840 United States;
SBI-087
Pfizer
2009 Phase 1 NCT00714116 Canada;United States;
SC belimumab
GlaxoSmithKline
2017 - NCT03125486 United States;
SM101
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
SM934
RenJi Hospital
2019 Phase 2 NCT03951259 China;
SQ Fludarabine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1998 Phase 1 NCT00001676 United States;
STELARA®
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
Sifalimumab
ASTRAZENECA
2011 - EUCTR2010-024069-30-IT Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States;
AstraZeneca AB
2012 - EUCTR2010-024069-30-BG Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 Phase 2 EUCTR2010-024069-30-GB Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-NL Argentina;Brazil;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-ES Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-DE Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
- - EUCTR2010-024069-30-HU Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
MedImmune LLC
2010 Phase 2 NCT00979654 Brazil;Canada;Chile;United States;
Sifalimumab 1,
MedImmune LLC
2011 Phase 2 NCT01283139 Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
Simvastatin
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Merck Sharp & Dohme Corp.
2007 Phase 4 NCT00739050 -
Ramathibodi Hospital
2008 Phase 4 NCT00866229 Thailand;
Sirolimus
Chinese SLE Treatment And Research Group
2020 Phase 2 NCT04582136 -
State University of New York - Upstate Medical University
2021 Phase 2 NCT04736953 -
Soluble Fc receptor
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
Soluble Fc-gamma receptor IIb
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
Standard dose of HCQ
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
Standard dose of rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 4 NCT04127747 China;
Standard of care
Peking Union Medical College Hospital
2021 Phase 4 NCT04956484 China;
Standard therapy
GlaxoSmithKline
2021 Phase 4 NCT04908865 -
Human Genome Sciences Inc., a GSK Company
2011 Phase 3 NCT01484496 Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
RemeGen Co., Ltd.
2022 Phase 1 NCT05247203 China;
Standard therapy (Excluding Immunosuppressants)
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Standard therapy (Including Immunosuppressants)
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Standard-of-care treatment
Janssen Research & Development, LLC
2021 Phase 2 NCT04882878 Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Stelara
Janssen-Cilag International NV
2019 Phase 3 EUCTR2017-001489-53-PT Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-PL Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-LT Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-HU Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-ES Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-DE Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-BG Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
Steroid Drug
Mallinckrodt
2013 Phase 4 NCT01753401 United States;
Steroid Taper
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Subcuvia
Department of Rheumatology,University hospital,Lund
2007 - EUCTR2006-004892-36-SE Sweden;
Sugar pill
Guy's and St Thomas' NHS Foundation Trust
2006 Phase 4 NCT01101802 United Kingdom;
Sulfate
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Switch to Myfortic
Erasmus Medical Center
2007 Phase 3 NCT00504244 Netherlands;
TAB08
Theramab LLC
2016 Phase 2 NCT02711813 Russian Federation;
TACI-Fc5
Merck Serono International
2008 - EUCTR2007-003698-13-BG Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-FR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003698-13-ES Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-GB Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-NL Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-LV Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-LT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-GR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States;
- - EUCTR2007-003698-13-DE Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
Merck Serono SA - Geneva
2008 - EUCTR2007-003698-13-AT Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
TAK-079
Millennium Pharmaceuticals, Inc.
2018 Phase 1 NCT03724916 United States;
TJ202 injection
I-Mab Biopharma Co. Ltd.
2021 Phase 1 NCT05140824 China;
TLR7/8 Antagonist (10mg)
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
TLR7/8 Antagonist (2.5mg)
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
TRU-015
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 1 NCT00479622 United States;
TV-4710
TEVA
2005 - EUCTR2005-001391-12-IT Germany;Hungary;Italy;Spain;United Kingdom;
TEVA Pharmaceutical Industries, Ltd.
2005 Phase 2 EUCTR2005-001391-12-GB Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2005-001391-12-ES Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-HU Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-DE Germany;Hungary;Italy;Spain;United Kingdom;
Tabalumab Auto-Injector
Eli Lilly and Company
2014 Phase 3 NCT02041091 Korea, Republic of;Mexico;Puerto Rico;United States;
Tabalumab Prefilled Syringe
Eli Lilly and Company
2014 Phase 3 NCT02041091 Korea, Republic of;Mexico;Puerto Rico;United States;
Tacrolimus
Chinese University of Hong Kong
2004 Phase 4 NCT00125307 China;Hong Kong;
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2010 - JPRN-UMIN000004182 Japan;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
The University of Hong Kong
2015 - JPRN-UMIN000025328 Japan,Asia(except Japan);
Telitacicept
RemeGen Co., Ltd.
2022 Phase 1 NCT05247203 China;
Thalidomide
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
The generic name is warfarin and many producers will be involved
University College London
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
Tocilizumab
Hoffmann-La Roche
2022 Phase 1 NCT05155345 Moldova, Republic of;Ukraine;United States;
Tocopherol acetate
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Toctino®
Universitätsklinikum Münster
2011 - EUCTR2010-024131-16-DE Germany;
Tofacitinib
Children's Hospital Medical Center, Cincinnati
2017 Phase 1/Phase 2 NCT03288324 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1 NCT05048238 United States;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2015 Phase 1 NCT02535689 United States;
Tofacitinib citrate
Tufts Medical Center
2017 Early Phase 1 NCT03159936 United States;
Trade Name Xarelto
University College London
2019 Phase 2;Phase 3 EUCTR2018-001735-49-GB United Kingdom;
Trade name Xarelto
University College London
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
Trimethoprim-Sulfamethoxazole
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2017 Phase 4 NCT03042260 Mexico;
Triptorelin pamoate
Children's Hospital Medical Center, Cincinnati
2003 Phase 2 NCT00124514 Brazil;United States;
Upadacitinib
AbbVie
2020 Phase 2 NCT04451772 Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03978520 Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
Yamazaki Hayato
2020 Phase 2 JPRN-jRCT2031210119 Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States;
Urine sample
University Hospital, Bordeaux
2018 - NCT03575156 France;
Ustekinumab
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183973 Japan, Asia except Japan, North America, South America, Europe, Africa;
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
Ustekinumab (approximately 6 mg/kg)
Janssen Research & Development, LLC
2020 Phase 3 NCT04060888 China;
2018 Phase 3 NCT03517722 Argentina;Australia;Bulgaria;Canada;China;Colombia;Ecuador;France;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
Ustekinumab 90 milligram (mg)
Janssen Research & Development, LLC
2020 Phase 3 NCT04060888 China;
Ustekinumab IV
Janssen Research & Development, LLC
2015 Phase 2 NCT02349061 Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States;
Ustekinumab SC
Janssen Research & Development, LLC
2015 Phase 2 NCT02349061 Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States;
VAY736
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharmaceuticals
2018 Phase 2 NCT03656562 Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
VIB7734
Viela Bio
2021 Phase 2 NCT04925934 Argentina;Greece;Mexico;Poland;Spain;Ukraine;United States;
2018 Phase 1 NCT03817424 Poland;Spain;United States;
VIB7734, MEDI7734
Viela Bio, Inc.
2021 Phase 2 EUCTR2020-005528-12-ES Argentina;Greece;India;Mexico;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
VIP
MONDOGEN AG
2008 - EUCTR2007-003621-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
MondoGEN AG
2009 - EUCTR2007-003621-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-003621-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Vaccination
Tuen Mun Hospital
2015 - NCT02477254 China;
Vaccine
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT01072734 France;
Versus hydroxychloroquine
Assistance Publique - Hôpitaux de Paris
2007 Phase 4 NCT00413361 France;
Vitamin D
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Vitamin D 25(OH)D
Faculty of Medicine, University of Alexandria
2010 - NCT01425775 Egypt;
Vitamin D2 ( calciferol )
Rajavithi Hospital
2021 - NCT05260255 Thailand;
Vitamin D3
National Institute of Allergy and Infectious Diseases (NIAID)
2008 Phase 2 NCT00710021 United States;
Vitamin D3 400 IU
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01709474 United States;
Vitamin D3 6000 IU
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01709474 United States;
Vitamins: B6, B12, and folate
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Vobarilizumab
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
Warfarin
University College, London
2020 Phase 2/Phase 3 NCT03684564 -
XmAb5871
Xencor, Inc.
2016 Phase 2 NCT02725515 United States;
Zishenqing
Shanghai University of Traditional Chinese Medicine
2019 Phase 2/Phase 3 NCT04275193 China;
Zostavax
Tuen Mun Hospital
2015 Phase 4 NCT02477150 China;
Zostavax vaccine
Oklahoma Medical Research Foundation
2011 Phase 1 NCT01474720 United States;
Centocor Research & Development, Inc.
2007 Phase 1 NCT01702740 -
2-deoxy-2 [F-18] fluoro-2-d-glucose
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 - NCT00029926 United States;
A-623
Anthera Pharmaceuticals
2011 Phase 2 NCT01305746 Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States;
2010 Phase 2 NCT01162681 Argentina;Brazil;Chile;Colombia;Hong Kong;India;Mexico;Peru;Philippines;Taiwan;United States;
ABBV-105
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-HU Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-ES Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
ABETIMUS SODIUM
AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
2009 - EUCTR2008-004852-62-IT Italy;
ABR-215757
Active Biotech Research AB
2009 - EUCTR2009-011245-55-SE Denmark;Sweden;
2009 - EUCTR2009-011245-55-DK Denmark;Sweden;
ABT-199
AbbVie (prior sponsor, Abbott)
2012 Phase 1 NCT01686555 Germany;Mexico;Puerto Rico;United States;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-HU Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-ES Argentina;Australia;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AC0058TA
ACEA Therapeutics, Inc.
2018 Phase 1 NCT03878303 United States;
ACM
Manuel Praga Terente
2010 - EUCTR2009-017273-38-ES Spain;
ACT-334441
ACTELION Pharmaceuticals Ltd
2015 Phase 2 EUCTR2014-002984-14-BG Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States;
IDORSIA PHARMACEUTICALS LTD
2019 Phase 2 EUCTR2018-001808-11-IT Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd
2020 Phase 2 EUCTR2018-001808-11-GR Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-PL Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-HU Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-FR Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-ES Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-DE Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-BG Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2018-001808-11-GB Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
AGS-009
Argos Therapeutics
2009 Phase 1 NCT00960362 Sweden;United States;
AIDSVAX® B/E
National Institute of Allergy and Infectious Diseases (NIAID)
2018 Phase 1 NCT03618056 United States;
AKBM-3031
Aker Biomarine Antarctic AS
2018 - NCT03626311 Canada;United States;
ALDESLEUCHINA
ILTOO PHARMA
2017 Phase 2 EUCTR2016-000488-17-IT Austria;Bulgaria;France;Italy;Portugal;Spain;
ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2017-001400-29-FR France;
ALPN-101
Alpine Immune Sciences, Inc.
2022 Phase 2 EUCTR2020-004047-86-HU France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 NCT04835441 Korea, Republic of;Poland;United States;
2021 Phase 2 EUCTR2020-004047-86-PL France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-ES France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
- Phase 2 EUCTR2020-004047-86-FR France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
ALX-0061
Ablynx
2015 Phase 2 NCT02437890 Argentina;Chile;Czech Republic;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
ALX-0061 150 mg/mL
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-PT Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-ES Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
AMG 557
Amgen
2012 Phase 1 NCT01683695 Australia;Denmark;France;Germany;Malaysia;Singapore;Taiwan;United Kingdom;United States;
2008 Phase 1 NCT00774943 Canada;United States;
2006 Phase 1 NCT02391259 United Kingdom;United States;
AMG 570
AMGEN INC.
2019 Phase 2 EUCTR2019-000328-16-IT Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
Amgen
2016 Phase 1 NCT02618967 United States;
Amgen Inc
2021 Phase 2 EUCTR2019-000328-16-GR Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000328-16-PT Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000328-16-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Switzerland;United Kingdom;United States;
AMG 592
AMGEN INC.
2021 Phase 2 EUCTR2020-003509-72-IT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
Amgen Inc.
2021 Phase 2 EUCTR2020-003509-72-PL Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-GR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-FR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-ES Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-BG Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-AT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
AMG 623
Amgen
2005 Phase 1 NCT02411136 -
2004 Phase 1 NCT02443506 -
AMG 811
Amgen
2009 Phase 1 NCT00818948 France;Hong Kong;Malaysia;Mexico;Singapore;United States;
2007 Phase 1 NCT02291588 -
AMG592
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-002564-40-DE France;Germany;Poland;United States;
AMG811
Amgen
2010 Phase 1 NCT01164917 United States;
ASF-1096 Cream
Astion Danmark A/S
2007 - EUCTR2006-001062-17-SE Sweden;United Kingdom;
Astion Pharma A/S
2007 - EUCTR2007-004635-29-SE Denmark;Spain;Sweden;
2007 - EUCTR2007-004635-29-DK Denmark;Spain;Sweden;
Abatacept
Bristol Myers Squibb International Corporation
2006 - EUCTR2004-004051-19-IT Germany;Italy;Sweden;United Kingdom;
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
2005 Phase 2 NCT00119678 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
Oklahoma Medical Research Foundation
2014 Phase 2 NCT02270957 United States;
Abatacept also known as Orencia also known as CTLA4-Ig
University of California, Los Angeles
2015 Phase 1/Phase 2 NCT02429934 United States;
Abetimus Sodium
La Jolla Pharmaceutical Company
2008 - EUCTR2006-000674-73-BG Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2006 Phase 3 EUCTR2006-000674-73-SK Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain;
Abetimus sodium
LA JOLLA PHARMACEUTICAL COMPANY
2008 - EUCTR2006-000674-73-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
Abetimus sodium (LJP 394)
La Jolla Pharmaceutical Company
2006 Phase 2 NCT00390091 United States;
2004 Phase 3 NCT00089804 Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States;
2001 Phase 3 NCT00035308 Austria;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States;
Acazicolcept
Alpine Immune Sciences, Inc.
2022 Phase 2 EUCTR2020-004047-86-HU France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-PL France;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
2021 Phase 2 EUCTR2020-004047-86-ES France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
- Phase 2 EUCTR2020-004047-86-FR France;Germany;Korea, Republic of;Poland;Russian Federation;Spain;United States;
Acetaminophen
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
Acetaminophen/Paracetamol
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Acthar
Mallinckrodt
2013 Phase 4 NCT01753401 United States;
Acthar Gel
Mallinckrodt
2016 Phase 4 NCT02953821 Argentina;Chile;Colombia;Mexico;Peru;United States;
Acthar high dose (80 U)
NYU Langone Health
2016 Phase 4 NCT02779153 United States;
Acthar low dose (40 U)
NYU Langone Health
2016 Phase 4 NCT02779153 United States;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Administration of methylprednisolone, paracetamol and dexchlorpheniramine
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Aldesleukin
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
Allogeneic MSC (AlloMSC)
Nanjing Medical University
2007 Phase 1/Phase 2 NCT00698191 China;
Allogeneic Stem Cell Transplantation
Northwestern University
2004 Phase 1 NCT00278590 United States;
Allogeneic bone marrow transplant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Alpha-tocopherol
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Anifrolumab
ASTRAZENECA AB
2015 Phase 3 EUCTR2014-004633-96-IT Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca
2021 Phase 3 NCT04931563 China;Hong Kong;Korea, Republic of;Philippines;Taiwan;Thailand;
2021 Phase 1 NCT05001698 China;
2021 - NCT04750057 -
2017 Phase 3 JPRN-JapicCTI-173544 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2017 Phase 2 NCT02962960 Hungary;Korea, Republic of;Poland;United States;
2016 Phase 3 NCT02794285 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 JPRN-JapicCTI-153064 Japan, Asia except Japan, North America, South America, Europe, Africa;
2015 Phase 3 NCT02446912 Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 NCT02446899 Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
AstraZeneca AB
2017 Phase 3 EUCTR2016-000625-39-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-RO Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-PL Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-HU Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-GB Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004633-96-DE Argentina;Australia;Brazil;Chile;Colombia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Taiwan;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2014-004632-19-LT Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-CZ Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
2015 Phase 3 EUCTR2014-004632-19-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Korea, Republic of;Lithuania;Mexico;Russian Federation;Singapore;South Africa;Spain;United States;
Astrazeneca AB
2016 Phase 2 EUCTR2016-003246-93-HU Hungary;Korea, Republic of;Poland;United States;
Hibi Kazushige
2021 Phase 3 JPRN-jRCT2071210076 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russia;Spain;Ukraine;United Kingdom;United States;
MedImmune LLC
2013 Phase 2 NCT01753193 Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2012 Phase 2 NCT01438489 Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
2014 Phase 2 EUCTR2012-004619-30-BG Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-HU Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
Oklahoma Medical Research Foundation
2021 Early Phase 1 NCT04726553 United States;
Anti BAFF (B cell activating factor)
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Anti LP40 antibody, subclass IgG4
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
Anti LP40 anticuerpo, subclase IgG4
Eli Lilly and Company
2011 - EUCTR2010-022100-42-ES Hungary;Latvia;Spain;United Kingdom;
Anti-CD19-CAR-T cells
Shanghai GeneChem Co., Ltd.
2017 Phase 1 NCT03030976 China;
Anti-CD20 B cell depletion with Truxima
Leiden University Medical Center
2018 Phase 2;Phase 3 EUCTR2018-001392-21-NL Netherlands;
Anti-CD28dAb
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Anti-CD28dab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-IT Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Baxalta now part of Shire
2011 Phase 1 NCT01541670 Australia;Canada;Mexico;New Zealand;United States;
Anti-blood dendritic cell antigen 2
Biogen Idec Research Limited
2017 Phase 2 EUCTR2015-004359-32-PL Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2017 Phase 2 EUCTR2015-004359-32-BG Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Aspirin
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Tuen Mun Hospital
2006 Phase 4 NCT00371501 Hong Kong;
Aspirin and meloxicam
Vanderbilt University
2005 Phase 1 NCT00731302 United States;
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University
2021 Early Phase 1 NCT05030779 China;
Atacicept
EMD Serono
2014 Phase 2 NCT02070978 Argentina;Brazil;Bulgaria;Chile;Czechia;Germany;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2012 Phase 2 NCT01440231 United States;
2008 Phase 2/Phase 3 NCT00624338 Argentina;Australia;Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Merck Serono International
2008 - EUCTR2007-003698-13-BG Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-FR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003698-13-ES Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-GB Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-NL Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-LV Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-LT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-GR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States;
- - EUCTR2007-003698-13-DE Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
Merck Serono SA - Geneva
2008 - EUCTR2007-003698-13-AT Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Atacicept 75 milligram (mg)
EMD Serono
2013 Phase 2 NCT01972568 Argentina;Brazil;Bulgaria;Chile;Czech Republic;Czechia;Germany;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Atorvastatin
Buddhist Tzu Chi General Hospital
2007 Phase 2/Phase 3 NCT00432354 Taiwan;
Johns Hopkins University
2002 Phase 4 NCT00120887 United States;
NYU Langone Health
2002 Phase 2 NCT00412841 United States;
The Center for Rheumatic Disease, Allergy, & Immunology
2007 Phase 1/Phase 2 NCT00519363 United States;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INC-17011497 China;
Autologous CD34+HPC transplantation (HSCT)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Autologous EBV specific CTL infusion
Nantes University Hospital
2016 Phase 1/Phase 2 NCT02677688 France;
Autologous Hematopoietic Stem Cell Transplantation
European Society for Blood and Marrow Transplantation
2009 Phase 2/Phase 3 NCT05063513 France;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous hematopoietic stem cell transplantation
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Aviptadil
MONDOGEN AG
2008 - EUCTR2007-003621-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
MondoGEN AG
2009 - EUCTR2007-003621-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-003621-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Azathioprine
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
Hospital Universitari Vall d'Hebron Research Institute
2009 Phase 4 NCT01112215 Spain;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
BENLYSTA? (belimumab)
GlaxoSmithKline, S.A.
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
BENLYSTA™ (belimumab)
GlaxoSmithKline Research & Development Ltd
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
BI 705564
Boehringer Ingelheim
2019 Phase 1 NCT03771885 -
BIIB059
BIOGEN IDEC RESEARCH LIMITED
2021 Phase 3 EUCTR2020-005776-35-IT Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States;
Biogen
2021 Phase 3 NCT04961567 Argentina;Bulgaria;Colombia;Czechia;Hungary;Japan;United States;
2021 Phase 3 NCT04895241 Bulgaria;China;Poland;Spain;United States;
2016 Phase 2 NCT02847598 Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2014 Phase 1 NCT02106897 United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-005776-35-NL Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005776-35-HU Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005775-12-GR Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2021 Phase 3 EUCTR2020-005775-12-ES Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2017 Phase 2 EUCTR2015-004359-32-PL Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
2017 Phase 2 EUCTR2015-004359-32-BG Argentina;Bulgaria;Colombia;Israel;Korea, Republic of;Mexico;Philippines;Poland;Serbia;Taiwan;Thailand;United States;
BMS-188667
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
BMS-931699
Bristol-Myers Squibb
2014 Phase 2 NCT02265744 Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-IT Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-HU Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2014 Phase 2 EUCTR2014-002184-14-ES Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
BMS-986165
Bristol-Myers Squibb
2019 Phase 2 NCT03920267 Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 1 NCT03541564 United States;
2017 Phase 2 NCT03252587 Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States;
2017 Phase 1 NCT03262727 United States;
Bristol-Myers Squibb International Corporation
2020 Phase 2 EUCTR2018-003471-35-ES Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-RO Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Israel;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-PL Argentina;Brazil;Canada;Colombia;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2018-003471-35-HU Argentina;Brazil;Canada;Colombia;Hungary;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2019 Phase 2 EUCTR2017-001203-79-ES Argentina;Australia;Brazil;Canada;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 2 EUCTR2017-001203-79-PL Argentina;Australia;Brazil;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
2018 Phase 2 EUCTR2017-001203-79-DE Argentina;Australia;Brazil;Canada;Colombia;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;United States;
Bristol-Myers Squibb international Corporation
2017 Phase 2 EUCTR2017-001203-79-HU Argentina;Brazil;Bulgaria;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United States;
BMS-986165 Capsule
Bristol-Myers Squibb
2017 Phase 1 NCT03254784 Netherlands;United States;
BMS-986165 Tablet
Bristol-Myers Squibb
2017 Phase 1 NCT03254784 Netherlands;United States;
BMS-986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986256
Ranganathan Usha
2022 Phase 2 JPRN-jRCT2011210069 Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;USA;United Kingdom;
BMS-986256 (Oral)
Bristol-Myers Squibb
2021 Phase 2 NCT04895696 Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
BMS-986256-06, TLR7/8 Antagonist
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
BMS986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
BOS161721
Boston Pharmaceuticals
2018 Phase 1/Phase 2 NCT03371251 Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
Boston Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2018-000305-23-HU Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
2019 Phase 2 EUCTR2018-000305-23-BG Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
BR-DIM
North Shore Long Island Jewish Health System
2016 Phase 1 NCT02483624 -
BT063
Biotest
2015 Phase 2 NCT02554019 Belarus;Georgia;Poland;Serbia;
Biotest AG
2015 Phase 2 EUCTR2014-005526-35-PL Belarus;Georgia;Poland;Serbia;
Baricinitib
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Baricitinib
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Eli Lilly Japan K.K.
2016 Phase 2 JPRN-JapicCTI-163359 -
- Phase 3 JPRN-JapicCTI-184095 -
Eli Lilly and Company
2019 Phase 3 NCT03843125 Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 3 NCT03616964 Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 NCT03616912 Australia;Austria;Belgium;Brazil;China;Croatia;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02708095 Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Spain;Taiwan;United States;
Belimumab
Affiliated Hospital of Guilin Medical College
2021 Phase 4 ChiCTR2100043138 China;
Biomedical Research Foundation, Academy of Athens
2020 - NCT04570306 -
First Affiliated Hospital Xi'an Jiaotong University
2022 Phase 4 NCT04893161 -
GlaxoSmithKline
2021 Phase 4 NCT04908865 -
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2017 Phase 1 NCT02880852 China;
2014 Phase 3 NCT02119156 China;Japan;Korea, Republic of;United States;
2012 Phase 3 NCT01597622 Japan;Korea, Republic of;
2012 Phase 2 NCT01649765 Argentina;Brazil;Canada;Italy;Japan;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - NCT01532310 United States;
2011 Phase 3 NCT01345253 China;Japan;Korea, Republic of;
2009 - NCT01914770 -
HUMAN GENOME SCIENCES INC
2009 Phase 3 EUCTR2007-007648-85-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences Inc.
2007 Phase 3 NCT00424476 Argentina;Australia;Brazil;Bulgaria;Chile;China;Colombia;Hong Kong;India;Korea, Republic of;Peru;Philippines;Romania;Russian Federation;Taiwan;
2006 Phase 3 NCT00410384 Austria;Belgium;Canada;Costa Rica;Czech Republic;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2003 Phase 2 NCT00071487 Canada;United States;
2002 Phase 1 NCT00657007 United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-SE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-DK Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences Inc., a GSK Company
2011 - NCT01858792 -
2008 Phase 3 NCT00724867 Canada;United States;
2008 Phase 3 NCT00712933 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Costa Rica;Czech Republic;Czechia;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2005 Phase 2 NCT00583362 Canada;United States;
Human Genome Sciences, Inc.
2012 - EUCTR2011-003814-18-ES Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
2012 Phase 3 EUCTR2011-003814-18-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Ishii Tomonori
2021 - JPRN-jRCTs021210042 Japan;
Oklahoma Medical Research Foundation
2014 Phase 4 NCT02270970 United States;
Peking Union Medical College Hospital
2021 Phase 4 NCT04956484 China;
Peking University People's Hospital
2022 Phase 3 NCT05262686 China;
RenJi Hospital
2021 Phase 4 NCT04515719 China;
University College London
2016 Phase 2 EUCTR2015-005543-14-GB United Kingdom;
Belimumab 10 mg/kg plus standard therapy
GlaxoSmithKline
2012 Phase 4 NCT01705977 Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;Indonesia;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Ukraine;United States;
Human Genome Sciences Inc., a GSK Company
2013 Phase 4 NCT01632241 Brazil;Colombia;France;South Africa;United Kingdom;United States;
Belimumab 100 mg SC
Human Genome Sciences Inc.
2008 Phase 2 NCT00732940 Mexico;United States;
Belimumab 200 mg SC
Human Genome Sciences Inc., a GSK Company
2011 Phase 3 NCT01484496 Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Belimumab 200 mg/mL
GlaxoSmithKline
2013 Phase 1 NCT01894360 United States;
Belimumab Injection
Leiden University Medical Center
2018 Phase 2 NCT03747159 Netherlands;
Belimumab Injection [Benlysta]
National University Hospital, Singapore
2020 Phase 4 NCT04447053 Singapore;
Belimumab autoinjector
GlaxoSmithKline
2014 Phase 2 NCT02124798 United States;
Belimumab for IV
GlaxoSmithKline
2019 Phase 1 NCT04136145 China;
Belimumab for SC
GlaxoSmithKline
2019 Phase 1 NCT04136145 China;
Belimumab or benlysta
Leiden University Medical Center
2018 Phase 2;Phase 3 EUCTR2018-001392-21-NL Netherlands;
Belimumab plus Early Vaccination
Human Genome Sciences Inc., a GSK Company
2012 Phase 4 NCT01597492 United States;
Belimumab plus Late Vaccination
Human Genome Sciences Inc., a GSK Company
2012 Phase 4 NCT01597492 United States;
Benazepril Pill
Northwell Health
2021 Phase 2 NCT04486118 United States;
Benlysta
GlaxoSmithKline
2018 - NCT03370263 Japan;
HUMAN GENOME SCIENCES INC
2012 - EUCTR2011-003814-18-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-SE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-DK Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc.
2012 - EUCTR2011-003814-18-ES Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-003814-18-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)
2012 Phase 3 EUCTR2011-003814-18-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc
2012 Phase 3 EUCTR2011-003814-18-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-003814-18-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Malaysia;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Leiden University Medical Center
2014 Phase 2 EUCTR2014-000488-42-NL Netherlands;
Benlysta (Belimumab)
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
Benlysta (belimumab)
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2013 - EUCTR2011-000368-88-IT Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Spain;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Benlysta 400 mg powder for concentrate for solution for infusion
GlaxoSmithKline, LLC
2013 Phase 4 EUCTR2011-005667-25-PT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-LT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-HU Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-BG Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
HUMAN GENOME SCIENCES INC
2013 - EUCTR2011-005667-25-IT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;European Union;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Philippines;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2014 Phase 4 EUCTR2011-005667-25-PL Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-SK Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-EE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-RO Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-ES Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2013 Phase 3;Phase 4 EUCTR2011-005672-42-GB Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States;
Benlysta 400 mg powder for concentrate for solution for infusions
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Benlysta®
Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP)
2021 Phase 4 EUCTR2021-001802-30-DE Germany;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Blisibimod
Anthera Pharmaceuticals
2016 Phase 3 NCT02514967 Georgia;
2015 Phase 3 NCT02074020 -
2013 Phase 3 NCT01395745 Belarus;Brazil;Colombia;Georgia;Guatemala;Hong Kong;India;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Singapore;Sri Lanka;Taiwan;Thailand;
Blood sample
University Hospital, Bordeaux
2021 - NCT04276701 France;Germany;Spain;
2020 - NCT04440566 France;
2018 - NCT03575156 France;
Bone densitometry
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Bortezomib
Charite University, Berlin, Germany
2014 Phase 2 NCT02102594 Germany;
Tohoku university hospital
2014 Phase 2 JPRN-UMIN000013508 Japan;
2013 Phase 2 JPRN-UMIN000012227 Japan;
Branebrutinib
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Brentuximab vedotin
Seagen Inc.
2015 Phase 2 NCT02533570 United States;
Brepocitinib
PFIZER INC
2021 Phase 2 EUCTR2018-004175-12-IT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Pfizer Inc.
2019 Phase 2 EUCTR2018-004175-12-PT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-PL Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-DE Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-BG Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Bronchoalveolar lavage (BAL fluid)
McGill University Health Centre/Research Institute of the McGill University Health Centre
2021 - NCT05007340 Canada;
Busulfan
New York Medical College
2007 Phase 1 NCT00684255 United States;
CC-220
Celgene
2017 Phase 2 NCT03161483 Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2014 Phase 2 NCT02185040 United States;
Celgene Corporation
2017 Phase 2 EUCTR2016-004574-17-HU Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-FR Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-ES Argentina;Belgium;Brazil;Canada;Colombia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-DE Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
2017 Phase 2 EUCTR2016-004574-17-BE Argentina;Belgium;Brazil;Canada;Colombia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Spain;United States;
CD34+ Peripheral Blood Stem Cell Reinfusion
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
CDP3194
UCB Inc
2008 Phase 2 EUCTR2007-002589-37-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-002589-37-BE Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-LT Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 - EUCTR2007-002589-37-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
UCB Inc.
2012 Phase 3 EUCTR2010-020859-30-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-020859-30-EE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-018563-41-LT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2012 - EUCTR2010-018563-41-EE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 Phase 3 EUCTR2010-020859-30-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-018565-26-GB Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 Phase 3 EUCTR2010-018563-41-GB Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-020859-30-LT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020859-30-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-020859-30-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-018565-26-IT Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-HU Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-ES Germany;Hungary;Italy;Spain;United Kingdom;
2011 - EUCTR2010-018565-26-DE Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018563-41-IT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-018563-41-DE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-CZ Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BG Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
CDP7657
UCB Biopharma SPRL
2016 Phase 2 EUCTR2015-004457-40-PL Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-HU Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-ES Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-DE Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-BG Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003409-83-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003406-27-DK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003406-27-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-PT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003409-83-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-FR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
UCB Pharma
2013 Phase 1 NCT01764594 Belgium;Bulgaria;Germany;Poland;Romania;Russian Federation;Spain;
2010 Phase 1 NCT01093911 Belgium;Bulgaria;Germany;
CEP-33457
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
CFZ533
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharmaceuticals
2018 Phase 2 NCT03656562 Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
CNTO1275
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
COVID-19 vaccine
Paul R Fortin
2022 Phase 2/Phase 3 NCT05236491 -
CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)
Hanyang University Seoul Hospital
2019 Phase 2 NCT04835883 Korea, Republic of;
CSM allogéniques issues de cordons ombilicaux ( MTI-PP)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2018 Phase 1;Phase 2 EUCTR2017-001400-29-FR France;
CTLA4-IgG4m (RG2077)
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 1/Phase 2 NCT00094380 United States;
CTLA4Ig
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
2005 - EUCTR2004-004051-19-SE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-GB Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-DE Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-BE Austria;Belgium;Germany;Italy;Sweden;United Kingdom;
2005 - EUCTR2004-004051-19-AT Austria;Germany;Italy;Sweden;United Kingdom;
Calcitriol
Chinese University of Hong Kong
2008 Phase 4 NCT00508898 Hong Kong;
Guilan University of Medical Sciences
2013 Phase 2 NCT01863641 Iran, Islamic Republic of;
Calcium
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Campath
New York Medical College
2007 Phase 1 NCT00684255 United States;
CellCept
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Cellcept
Cambridge University Hospitals NHS Foundation Trust
2005 Phase 2 EUCTR2005-002207-16-GB United Kingdom;
Cenerimod
IDORSIA PHARMACEUTICALS LTD
2019 Phase 2 EUCTR2018-001808-11-IT Bulgaria;Chile;China;Colombia;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd
2020 Phase 2 EUCTR2018-001808-11-GR Bulgaria;Chile;China;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-PL Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-HU Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-FR Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-ES Bulgaria;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-DE Bulgaria;China;Czech Republic;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001808-11-BG Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2018-001808-11-GB Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Idorsia Pharmaceuticals Ltd.
2018 Phase 2 NCT03742037 Bulgaria;Chile;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 1/Phase 2 NCT02472795 Belarus;Bulgaria;Georgia;Russian Federation;Ukraine;United States;
Yokoyama Yoshinari
2021 Phase 2 JPRN-jRCT2011210019 Japan;
Cervarix suspensie voor injectie
University Medical Center Utrecht
2009 - EUCTR2008-008169-36-NL Netherlands;
Cholecalciferol
Assistance Publique - Hôpitaux de Paris
2010 - NCT01413230 France;
Medical University of South Carolina
2011 Phase 2 NCT01911169 United States;
2006 Phase 1 NCT00418587 United States;
ROSA MARIA RODRIGUES PEREIRA
2012 - NCT01892748 Brazil;
Cholecalciferol and C. Xanthorrhiza
Saiful Anwar Hospital
2016 - NCT03155477 -
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Clopidogrel
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Collection of samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Combination Product: Belimumab
GlaxoSmithKline
2019 Phase 2 NCT04179032 Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
1997 Phase 4 NCT00392093 Mexico;
Continuation of azathioprine
Erasmus Medical Center
2007 Phase 3 NCT00504244 Netherlands;
Corn starch
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Corticosteroids
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Corticosteroids (prednisone or prednisolone)
Bristol-Myers Squibb
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
Creatine
University of Sao Paulo
2011 - NCT01217320 Brazil;
Crestor
Imperial College
2010 Phase 4 EUCTR2006-006214-16-GB United Kingdom;
Csa
Manuel Praga Terente
2010 - EUCTR2009-017273-38-ES Spain;
Cumulative corticosteroid exposure
GlaxoSmithKline
2012 - NCT01616472 -
Curcumin supplement
Loma Linda University
2019 Phase 2 NCT03953261 United States;
Cyclophosphamide
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
Institute of Rheumatology, Prague
2002 Phase 2 NCT00976300 Czech Republic;
Istituto Giannina Gaslini
2006 - EUCTR2005-003957-28-DK Denmark;Italy;
Johns Hopkins University
1997 - NCT00010400 United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2004 Phase 1/Phase 2 NCT00094380 United States;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Shanghai GeneChem Co., Ltd.
2017 Phase 1 NCT03030976 China;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Sun Yat-sen University
2010 - NCT01060410 China;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Cyclophosphamide-prednisone-azathioprine
Istituto Giannina Gaslini
2006 Phase 3 NCT00336414 Italy;
Cyclosporin A
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Cyclosporine A
Institute of Rheumatology, Prague
2002 Phase 2 NCT00976300 Czech Republic;
Cymbalta
Dr. Jesus Gutierrez Stone
2010 - NCT01269866 United States;
Cytarabine
National Center for Research Resources (NCRR)
1995 Phase 2 NCT00004643 -
DELTACORTENE*20CPR
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
DS-7011a
Daiichi Sankyo, Inc.
2022 Phase 1 NCT05203692 United States;
DZP
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 NCT04294667 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
Dapagliflozin
Dept. Rheumatology, Renji Hospital South Campus
2018 Phase 4 study ChiCTR1800015030 China;
Dapirolizumab pegol
UCB Biopharma SRL
2022 Phase 3 EUCTR2019-003409-83-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003407-35-ES Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 3 EUCTR2019-003406-27-DK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 NCT04976322 Argentina;Bulgaria;Canada;Hungary;Poland;Spain;Taiwan;United States;
2021 Phase 3 EUCTR2019-003409-83-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003409-83-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2019-003406-27-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-PT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-ES Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003406-27-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003409-83-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003407-35-BE Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Italy;Japan;Poland;Portugal;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-FR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
- Phase 3 EUCTR2019-003406-27-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Romania;Serbia;Spain;Taiwan;United Kingdom;United States;
Dapirolizumab pegol (DZP)
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02804763 Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SPRL
2016 Phase 2 EUCTR2015-004457-40-PL Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-HU Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-ES Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-DE Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2015-004457-40-BG Bulgaria;Chile;Colombia;Germany;Hungary;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Daratumumab
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
Daratumumab Injection
Charite University, Berlin, Germany
2021 Phase 2 NCT04810754 -
Darzalex
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
Dehydroepiandrosterone
National Center for Research Resources (NCRR)
1996 Phase 3 NCT00004662 -
1995 Phase 2 NCT00004665 -
1994 Phase 2/Phase 3 NCT00004795 -
UMC Utrecht
2000 Phase 2 NCT00391924 Netherlands;
Dehydroepiandrosterone (DHEA)
University of Michigan
2003 Phase 2/Phase 3 NCT00189124 United States;
Depletion of CD3/CD19 in an autologous stem cell transplant
Stephan Grupp MD PhD
2021 Phase 2 NCT05029336 United States;
Dihydroartemisinin tablet
Kunming Pharmaceuticals, Inc.
2018 Phase 2 NCT03396393 -
Dimethylfumarat
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Diphenhydramine
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Diphenhydramine hydrochloride
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Docosahexaenoic acid
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Doppler ultrasound
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Groupe Hospitalier Pitie-Salpetriere
2018 - NCT03480529 France;
E6742
Eisai Co., Ltd.
2022 Phase 1/Phase 2 NCT05278663 Japan;
EPA and DHA supplementation
University of Sao Paulo
2014 - NCT01956188 Brazil;
ERL080A
Novartis Pharma Services AG
2006 - EUCTR2005-003070-19-HU Hungary;
Edratide
TEVA Pharmaceutical Industries, Ltd.
2005 Phase 2 EUCTR2005-001391-12-GB Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2005-001391-12-ES Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-HU Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-DE Germany;Hungary;Italy;Spain;United Kingdom;
Teva Pharmaceutical Industries
2005 Phase 2 NCT00203151 United States;
Edratide Acetate
TEVA
2005 - EUCTR2005-001391-12-IT Germany;Hungary;Italy;Spain;United Kingdom;
Efavaleukin alfa
Hama Yoriko
2021 Phase 2 JPRN-jRCT2041210076 Greece,;Japan;Korea, Republic of;Poland;Spain;Turkey;United States;
Eicosapentaenoic acid
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Elsubrutinib
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 2 EUCTR2020-001690-72-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000638-20-IT Argentina;Australia;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Romania;Spain;Taiwan;United Kingdom;United States;
AbbVie
2020 Phase 2 NCT04451772 Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03978520 Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-001690-72-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001690-72-BG Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-NL Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001690-72-HU Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Taiwan;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000638-20-DE Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
Emapalumab
Swedish Orphan Biovitrum
2021 Phase 3 NCT05001737 -
Enteric-Coated Mycophenolate Sodium
Hospital Universitari Vall d'Hebron Research Institute
2009 Phase 4 NCT01112215 Spain;
Epatuzumab
IMMUNOMEDICS
2005 - EUCTR2005-000706-31-IT Germany;Italy;Spain;United Kingdom;
Epratuzumab
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Inc
2008 Phase 2 EUCTR2007-002589-37-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-002589-37-BE Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-LT Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;
2008 - EUCTR2007-002589-37-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002589-37-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
UCB Inc.
2012 - EUCTR2010-020859-30-EE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-018563-41-LT Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2012 - EUCTR2010-018563-41-EE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 Phase 3 EUCTR2010-020859-30-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020859-30-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-018565-26-GB Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 Phase 3 EUCTR2010-018563-41-GB Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-020859-30-LT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020859-30-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-020859-30-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-018565-26-HU Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018565-26-ES Germany;Hungary;Italy;Spain;United Kingdom;
2011 - EUCTR2010-018565-26-DE Brazil;Canada;Germany;Hungary;India;Italy;Mexico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2011 - EUCTR2010-018563-41-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2010-018563-41-DE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-CZ Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BG Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
2011 - EUCTR2010-018563-41-BE Australia;Belgium;Brazil;Bulgaria;Czech Republic;Estonia;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Russian Federation;Spain;Taiwan;United Kingdom;
UCB Pharma
2012 Phase 2 NCT01534403 Japan;
2011 Phase 3 NCT01408576 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 1/Phase 2 NCT01449071 Japan;
2010 Phase 3 NCT01262365 Australia;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Estonia;France;Germany;India;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States;
2010 Phase 3 NCT01261793 Brazil;Canada;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2008 Phase 2 NCT00660881 Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States;
2008 Phase 2 NCT00624351 Belgium;Brazil;Hong Kong;Hungary;India;Lithuania;Poland;Spain;Ukraine;United Kingdom;United States;
2007 Phase 3 NCT00382837 Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;United States;
2006 Phase 2 NCT00383513 Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2005 Phase 3 NCT00383214 Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2005 Phase 3 NCT00111306 Belgium;Hungary;Netherlands;Spain;United Kingdom;United States;
2005 Phase 2 NCT00113971 United States;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
Epratuzumab iv
UCB Biopharma S.P.R.L.
2014 Phase 1 NCT02306629 United Kingdom;
Epratuzumab sc
UCB Biopharma S.P.R.L.
2014 Phase 1 NCT02306629 United Kingdom;
Ethinyl estradiol
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Ethylhydrogenfumarat, Calciumsalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Ethylhydrogenfumarat, Magnesiumsalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Ethylhydrogenfumarat, Zinksalz
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Evobrutinib
Merck KGaA
2017 Phase 2 EUCTR2016-002950-19-PL Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
Extended release dipyridamole 200mg/aspirin
Oklahoma Medical Research Foundation
2013 - NCT01781611 United States;
Ezetimibe+Simvastatin Drug Combination
Peking Union Medical College Hospital
2015 Phase 0 NCT02548936 China;
Fan beam CT scan
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Johns Hopkins University
1997 - NCT00010400 United States;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Northwestern Memorial Hospital
2001 Phase 1 NCT00017641 United States;
Flash glucose monitoring system
RenJi Hospital
2017 - NCT03296995 China;
Flow-mediated dilation of the brachial artery
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Fludarabine
New York Medical College
2007 Phase 1 NCT00684255 United States;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Fludarabine phosphate
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Fluzone
University of Alabama at Birmingham
2007 - NCT00611611 United States;
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Forigerimod
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
Fostamatinib Disodium (R935788)
Rigel Pharmaceuticals
2008 Phase 2 NCT00752999 -
Fumaderm®
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
Fumaderm® initial
Universitätsklinikum Münster
2011 - EUCTR2010-023645-29-DE Germany;
GC+HCQ
Peking Union Medical College Hospital
2016 - NCT02842814 China;
GDC-0853
Genentech, Inc.
2018 Phase 2 NCT03407482 Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 NCT02908100 Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;Thailand;United Kingdom;United States;
GDC-0853 RO7010939
Genentech, Inc.
2018 Phase 2 EUCTR2017-001764-37-PT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-PT Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-ES Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001039-11-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
Roche Farma, S.A por delegación de Genentech, Inc.
2017 Phase 2 EUCTR2017-001764-37-ES Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
GL701
Genelabs Technologies
1998 Phase 3 NCT00037128 United States;
GLPG3970 film-coated tablet
Galapagos NV
2020 Phase 1 NCT04700267 Bulgaria;Moldova, Republic of;Poland;Spain;Ukraine;
GSK1550188
GlaxoSmithKline Research & Development Ltd
2020 Phase 2 EUCTR2018-004645-16-NL Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2019 Phase 2 EUCTR2018-004645-16-DE Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2012 Phase 2 EUCTR2011-000368-88-GB Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
2012 - EUCTR2011-000368-88-NL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- Phase 2 EUCTR2011-000368-88-PL Argentina;Brazil;Canada;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
- - EUCTR2011-000368-88-Outside-EU/EEA Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GlaxoSmithKline, S.A.
2019 Phase 2 EUCTR2018-004645-16-ES Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2012 - EUCTR2011-000368-88-ES Argentina;Brazil;Canada;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
GSK1550188 1mg/kg or
GlaxoSmithKline
2010 Phase 1 NCT01381536 Japan;
GSK1550188 IV
GlaxoSmithKline
2011 Phase 1 NCT01516450 Japan;
GSK1550188 SC
GlaxoSmithKline
2011 Phase 1 NCT01516450 Japan;
GSK2586184
GlaxoSmithKline
2013 Phase 2 NCT01777256 Argentina;Brazil;Chile;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;Romania;South Africa;Spain;Sweden;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-001645-41-SE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-PL Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-DE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-CZ Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 Phase 2 EUCTR2012-001645-41-EE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden;
2012 - EUCTR2012-001645-41-HU Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 - EUCTR2012-001645-41-GR Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GlaxoSmithKline, S.A.
2012 - EUCTR2012-001645-41-ES Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GSK2586184 800mg single and repeat dose
GlaxoSmithKline
2012 Phase 1 NCT01687309 Belgium;
GSK2586184 new formulation
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
GSK2586184 standard formulation
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Gardasil
University of Chicago
2008 - NCT00786409 United States;
Wayne State University
2013 Phase 1 NCT01741012 United States;
Gazyvaro
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-005760-57-IT Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-005760-57-PL Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-005760-57-ES Argentina;Australia;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Gold
The Affiliated Drum Tower Hospital of Nanjing University Medical School
2021 Phase 0 ChiCTR2100048082 China;
Tianjin Children's Hospital
2020 - ChiCTR2000038519 China;
Group A SLE prospective study
Oklahoma Medical Research Foundation
2009 Phase 1/Phase 2 NCT00987831 United States;
Growth colony stimulating factor (G-CSF)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
H.P. Acthar Gel
Fiechtner, Justus J., M.D., P.C.
2012 Phase 4 NCT01769937 United States;
HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM
BIOGEN IDEC RESEARCH LIMITED
2021 Phase 3 EUCTR2020-005776-35-IT Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;United Kingdom;United States;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 - NCT04907175 United States;
HGS1006
HUMAN GENOME SCIENCES INC
2009 Phase 3 EUCTR2007-007648-85-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-IT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc
2009 Phase 3 EUCTR2007-007648-85-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc.
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
HLL2
UCB Inc
2008 Phase 2 EUCTR2007-002566-35-ES Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-LT Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-HU Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-GB Belgium;Hungary;Lithuania;Spain;United Kingdom;
2008 - EUCTR2007-002566-35-BE Belgium;Hungary;Lithuania;Spain;United Kingdom;
HLL2 (Epratuzumab)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2001 Phase 1 NCT00011908 United States;
HLL2 (trivial name or chemical description)
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
HLL2,IMMU-103
IMMUNOMEDICS
2005 - EUCTR2005-000706-31-IT Germany;Italy;Spain;United Kingdom;
HPV prophylactic vaccine Gardasil
University Hospital, Bordeaux
2012 Phase 2 NCT01687192 France;
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278538 United States;
High Dietary Sodium
Vanderbilt University
2018 - NCT02525835 United States;
High Dose Mesenchymal Stem Cells (MSCs)
Medical University of South Carolina
2018 Phase 2 NCT02633163 United States;
Hiomega-3 supplement of Naturalis® company -
Federal University of Minas Gerais
2009 - NCT02524795 -
HrIL-2 active
Peking University People's Hospital
2015 Phase 2 NCT02465580 China;
Human papillomavirus vaccination (Gardasil)
Tuen Mun Hospital
2009 Phase 4 NCT00911521 China;
Human umbilical cord derived MSC transplantation for SLE
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2012 Phase 1/Phase 2 NCT01741857 China;
Humanised IgG1 monoclonal antibody against blood dendritic cell antigen 2
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-005776-35-NL Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005776-35-HU Argentina;Belgium;Canada;China;Colombia;Czechia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Romania;Serbia;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005775-12-GR Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
2021 Phase 3 EUCTR2020-005775-12-ES Australia;Brazil;Bulgaria;Chile;France;Greece;Korea, Republic of;Mexico;Peru;Philippines;Poland;Russian Federation;Spain;Sweden;Taiwan;United States;
Hydroxychloroquine
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Department of Internal Medicine, Teikyo University School of Medicine
2014 - JPRN-UMIN000012478 Japan;
Ishii Tomonori
2021 - JPRN-jRCTs021210042 Japan;
Milton S. Hershey Medical Center
2017 Phase 2 NCT03030118 United States;
Nanjing University of Chinese Medicine Affiliated Hospital
2019 Phase 1 study ChiCTR1800020286 China;
2019 Phase 1 ChiCTR1900022934 China;
Renji Hospital, Shanghai JiaoTong University School of Medicine
2012 - ChiCTR-TRC-12002419 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Hydroxychloroquine (Z0188)
Sanofi
2012 Phase 3 NCT01551069 Japan;
Hydroxychloroquine or Chloroquine
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01946880 United States;
Hydroxychloroquine reduced
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
ICI 182,780 (Faslodex)
The Center for Rheumatic Disease, Allergy, & Immunology
2004 Phase 2 NCT00417430 United States;
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
2020 Phase 1/Phase 2 NCT04305197 China;
Innocare Pharma Australia Pty Ltd
2017 Phase 1 NCT03189017 Australia;
IFN-K
NEOVACS
2015 Phase 2 EUCTR2015-001341-86-IT Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
Neovacs
2010 Phase 1/Phase 2 NCT01058343 Belgium;Bulgaria;Croatia;France;Germany;Romania;Spain;Switzerland;
Neovacs S.A.
2017 Phase 2 EUCTR2015-001341-86-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2017 Phase 2 EUCTR2015-001341-86-BG Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-DE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-BE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
Neovas S.A.
2015 Phase 2 EUCTR2015-001341-86-HR Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States;
IFN-Kinoid
NEOVACS
2015 Phase 2 EUCTR2015-001341-86-IT Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
IFN-Kinoid Drug Substance
Neovacs S.A.
2017 Phase 2 EUCTR2015-001341-86-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2017 Phase 2 EUCTR2015-001341-86-BG Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-DE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
2015 Phase 2 EUCTR2015-001341-86-BE Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Thailand;Tunisia;Ukraine;United States;
Neovas S.A.
2015 Phase 2 EUCTR2015-001341-86-HR Argentina;Belgium;Bulgaria;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;Peru;Philippines;Poland;Russian Federation;Spain;Switzerland;Taiwan;Thailand;United States;
IFN-a 2b Kinoid Drug Substance
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
IFN-a2b Kinoid
Neovacs SA
2010 Phase 1;Phase 2 EUCTR2009-012059-47-FR Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-DE Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BG Belgium;Bulgaria;France;Germany;
2010 Phase 1;Phase 2 EUCTR2009-012059-47-BE Belgium;Bulgaria;France;Germany;
IFNa-Kinoid
Neovacs
2015 Phase 2 NCT02665364 Argentina;Belgium;Chile;Colombia;Croatia;France;Georgia;Germany;Italy;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Philippines;Poland;Russian Federation;Switzerland;Taiwan;Thailand;Tunisia;United States;
IL-2
The First Hospital of Jilin University
2020 - NCT04397107 China;
the Second Hospital of Shanxi Medical University
2016 - ChiCTR-IPR-16009451 China;
IL-6R nanobody
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-PT Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-ES Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
ILT-101
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-IT Austria;Bulgaria;France;Italy;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
Iltoo Pharma
2017 Phase 2 NCT02955615 Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
IMMU-103
Immunomedics, Inc.
2006 Phase 3 EUCTR2005-000705-59-HU Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000706-31-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000705-59-SK Germany;Hungary;Italy;Slovakia;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-GB Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000705-59-GB Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma Inc.
2006 - EUCTR2005-000706-31-DE Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000706-31-BE Belgium;Germany;Italy;Spain;United Kingdom;
UCB Pharma, Inc
2006 - EUCTR2005-000705-59-DE Germany;Hungary;Italy;Spain;United Kingdom;
IMMUNOGLOBULIN G
Boston Pharmaceuticals, Inc.
2019 Phase 2 EUCTR2018-000305-23-HU Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
2019 Phase 2 EUCTR2018-000305-23-BG Argentina;Bulgaria;Colombia;Georgia;Hungary;Mexico;Peru;Philippines;Poland;Romania;Ukraine;United States;
INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
INTERLEUKIN-2
ILTOO PHARMA
2018 Phase 2 EUCTR2016-000488-17-FR Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2017 Phase 2 EUCTR2016-000488-17-BG Austria;Bulgaria;France;Germany;Italy;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-PT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
2016 Phase 2 EUCTR2016-000488-17-ES Austria;Bulgaria;France;Italy;Mexico;Portugal;Spain;
2016 Phase 2 EUCTR2016-000488-17-AT Austria;Bulgaria;France;Germany;Italy;Mauritius;Mexico;Portugal;Romania;Spain;
IPP - 201101
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
IPP-201101
IMMUPHARMA
2016 Phase 3 EUCTR2015-003341-25-IT France;Germany;Hungary;Italy;United Kingdom;
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
ImmuPharma
2018 Phase 3 NCT03427151 Czechia;France;Germany;Hungary;Mauritius;Poland;Puerto Rico;United States;
2018 Phase 3 EUCTR2017-004060-35-HU Hungary;Mauritius;United States;
2015 Phase 3 NCT02504645 Czech Republic;Czechia;France;Germany;Hungary;Italy;Mauritius;Poland;Puerto Rico;United States;
ImmuPharma SA
2016 Phase 3 EUCTR2015-003341-25-HU France;Germany;Hungary;United States;
2016 Phase 3 EUCTR2015-003341-25-GB France;Germany;Hungary;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003341-25-FR France;Germany;Hungary;United States;
2016 Phase 3 EUCTR2015-003341-25-DE France;Germany;Hungary;United Kingdom;United States;
IPP-201101, P140
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
IS (B cell depletion therapy)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MMF or MPA)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
IS (MTX)
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Ianalumab
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Ibandronate+alfacalcidol+calcium
Chinese University of Hong Kong
2007 Phase 4 NCT00668330 China;
Immune ablation and hematopoietic stem cell support.
Richard Burt, MD
2002 Phase 2 NCT00271934 United States;
Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer
Astrazeneca AB
2017 Phase 2 EUCTR2016-003246-93-PL Hungary;Korea, Republic of;Poland;United States;
Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
Individualized dose of rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 4 NCT04127747 China;
Infliximab
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
Medical University of Vienna
2006 Phase 2/Phase 3 NCT00368264 Austria;Germany;Netherlands;
Influenz virus surface antigens
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
Influvac
University Medical Center Groningen
2007 - EUCTR2007-004579-21-NL Netherlands;
Intravenous immunoglobulin
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Iscalimab
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Itolizumab [Bmab 600]
Equillium
2019 Phase 1 NCT04128579 India;Poland;United States;
JBT-101
National Institute of Allergy and Infectious Diseases (NIAID)
2017 Phase 2 NCT03093402 United States;
JNJ-54767414
Charité - Universitätsmedizin Berlin
2021 Phase 2 EUCTR2021-000962-14-DE Germany;
JNJ-55920839
Janssen Research & Development, LLC
2015 Phase 1 NCT02609789 Belgium;Moldova, Republic of;Poland;Romania;Spain;Taiwan;United States;
JNJ-56022473
Janssen Research & Development, LLC
2017 Phase 1 NCT02920424 Germany;
JNJ-80202135
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
KPG-818
Kangpu Biopharmaceuticals, Ltd.
2019 Phase 1 NCT03949426 United States;
KPG-818 dose
Kangpu Biopharmaceuticals, Ltd.
2021 Phase 1/Phase 2 NCT04643067 United States;
KZR-616
Kezar Life Sciences, Inc.
2018 Phase 1/Phase 2 NCT03393013 Australia;Colombia;Mexico;Peru;Poland;Russian Federation;Ukraine;United States;
L04AA26
GlaxoSmithKline, LLC
2013 Phase 4 EUCTR2011-005667-25-PT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-LT Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-HU Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-BG Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2014 Phase 4 EUCTR2011-005667-25-PL Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-SK Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 Phase 4 EUCTR2011-005667-25-EE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-RO Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
2013 - EUCTR2011-005667-25-ES Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Estonia;Hong Kong;Hungary;India;Indonesia;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2013 Phase 3;Phase 4 EUCTR2011-005672-42-GB Brazil;Colombia;France;Martinique;South Africa;United Kingdom;United States;
LA294
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
LABP-104
Landos Biopharma Inc.
2021 Phase 1 NCT05019950 Australia;
LJP 394
LA JOLLA PHARMACEUTICAL COMPANY
2008 - EUCTR2006-000674-73-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
La Jolla Pharmaceutical Company
2008 - EUCTR2006-000674-73-PT Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-ES Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-DE Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-CZ Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2008 - EUCTR2006-000674-73-BG Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
2006 Phase 3 EUCTR2006-000674-73-SK Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Slovakia;Spain;
2006 - EUCTR2006-000674-73-HU Bulgaria;Czech Republic;Germany;Hungary;Italy;Portugal;Spain;
LJP394
AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
2009 - EUCTR2008-004852-62-IT Italy;
LY2127399
ELI LILLY
2011 - EUCTR2010-022099-29-IT Austria;Bulgaria;Germany;Italy;
ELI LILLY AND COMPANY
2013 - EUCTR2010-022101-18-IT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2014 - EUCTR2010-022101-18-HR Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2010-022101-18-DE Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 NCT01488708 United States;
2012 - EUCTR2010-022101-18-LV Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-HU Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-GB Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-ES Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-BG Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022101-18-AT Argentina;Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Ecuador;Egypt;France;Germany;Guatemala;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01205438 Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022100-42-GB Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-LV Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-HU Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom;United States;
2011 - EUCTR2010-022100-42-ES Hungary;Latvia;Spain;United Kingdom;
2011 - EUCTR2010-022099-29-DE Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-BG Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2011 - EUCTR2010-022099-29-AT Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Peru;Philippines;Poland;Singapore;Thailand;Turkey;Ukraine;United States;
2010 Phase 3 NCT01196091 Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, The Former Yugoslav Republic of;Peru;Philippines;Poland;Puerto Rico;Singapore;Thailand;Turkey;Ukraine;United States;
LY3009104
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-184095 -
Eli Lilly and Company
2020 Phase 3 EUCTR2017-005028-11-NL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-RO Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-PL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-GB Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-ES Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-NL Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-HR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GB Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-ES Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 EUCTR2017-005026-37-HU Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-CZ Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-BE Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-AT Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-PL Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-FR Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004404-35-AT Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States;
Lilly S.A.
2016 Phase 2 EUCTR2015-004404-35-ES Argentina;Austria;France;Japan;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United States;
LY3361237
Eli Lilly and Company
2022 Phase 2 NCT05123586 Argentina;Czechia;Mexico;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
2019 Phase 1 NCT03933943 United States;
LY3471851
Eli Lilly & Company
2021 Phase 2 EUCTR2019-003323-38-DE Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-PL Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-HU Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003323-38-GB Argentina;Australia;Canada;Czech Republic;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 2 NCT04433585 Argentina;Australia;Canada;Czechia;Germany;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 1 NCT03556007 United States;
Laquinimod
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
Teva Pharmaceutical Industries
2010 Phase 2 NCT01085084 Canada;United States;
Leflunomide
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Sanofi
2003 Phase 2 NCT00637819 Hong Kong;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Lenalidomide
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900025376 China;
Leukapheresis
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Levothyroxine
Johns Hopkins University
2011 Phase 4 NCT01276782 United States;
Lisinopril Pills
Northwell Health
2021 Phase 2 NCT04486118 United States;
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)
Bristol-Myers Squibb
2017 Phase 1 NCT03262727 United States;
Low Dietary Sodium
Vanderbilt University
2018 - NCT02525835 United States;
Low Dose Mesenchymal Stem Cells (MSCs)
Medical University of South Carolina
2018 Phase 2 NCT02633163 United States;
2017 Phase 1 NCT03171194 United States;
Low-dose Aldesleukin (Proleukin®)
Onur Boyman, MD
2018 Phase 2 NCT03312335 Switzerland;
Lulizumab pegol
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-002184-14-NL Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-002184-14-DE Argentina;Brazil;Canada;Chile;Colombia;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Romania;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb K.K.
2015 Phase 2 JPRN-JapicCTI-153077 Japan, Asia except Japan, North America, South America, Europe;
Lupuzor
Cephalon
2010 Phase 3 NCT01240694 Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States;
2010 Phase 2 NCT01135459 Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United Kingdom;United States;
Cephalon, Inc.
2011 Phase 3 EUCTR2010-019293-32-BE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2011 - EUCTR2010-019293-32-DE Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-PT Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-CZ Belgium;Czech Republic;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-PT Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
2010 - EUCTR2010-018383-16-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Portugal;Spain;Ukraine;United States;
LymphoStat-B
Human Genome Sciences, Inc
2009 Phase 3 EUCTR2007-007648-85-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Human Genome Sciences, Inc.
2010 Phase 3 EUCTR2007-007648-85-AT Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-GB Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-DE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;
2009 Phase 3 EUCTR2007-007648-85-BE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 1;Phase 3 EUCTR2007-007648-85-SE Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
2009 Phase 3 EUCTR2007-007648-85-NL Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
2009 Phase 3 EUCTR2007-007648-85-CZ Argentina;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
LymphoStat-B TM
Human Genome Sciences, Inc.
2007 Phase 3 EUCTR2006-005177-21-SK Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005177-21-ES Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-SE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005177-21-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
LymphoStat-B®, monoclonal anti-BLyS, LSB, BENLYSTA®
GlaxoSmithKline Research & Development Ltd
2020 Phase 2 EUCTR2018-004645-16-NL Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
2019 Phase 2 EUCTR2018-004645-16-DE Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
GlaxoSmithKline, S.A.
2019 Phase 2 EUCTR2018-004645-16-ES Argentina;Germany;Japan;Mexico;Netherlands;Spain;United States;
M281
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
M2951
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02975336 Argentina;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
Merck KGaA
2017 Phase 2 EUCTR2016-002950-19-PL Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
2017 Phase 2 EUCTR2016-002950-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mauritius;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Taiwan;United States;
M2951 (Other Name: Evobrutinib)
Merck Biopharma Co., Ltd
2017 Phase 2 JPRN-JapicCTI-183957 Japan, Asia except Japan, North America, South America, Europe, Africa;
M5049
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2020 Phase 1 NCT04647708 Bulgaria;Germany;Moldova, Republic of;Spain;Ukraine;
M5049 high dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
M5049 low dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
M5049 medium dose
EMD Serono Research & Development Institute, Inc.
2021 Phase 2 NCT05162586 Germany;United States;
MEDI 545
MedImmune LLC
2007 Phase 1 NCT00482989 Argentina;Brazil;Canada;Chile;United States;
2006 Phase 1 NCT00299819 Canada;United States;
MEDI-545
ASTRAZENECA
2011 - EUCTR2010-024069-30-IT Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States;
AstraZeneca AB
2012 - EUCTR2010-024069-30-BG Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 Phase 2 EUCTR2010-024069-30-GB Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-NL Argentina;Brazil;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-ES Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-DE Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
- - EUCTR2010-024069-30-HU Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
MedImmune LLC
2008 Phase 2 NCT00657189 United States;
2006 Phase 1 NCT00299819 Canada;United States;
MEDI-545 600
AstraZeneca
2009 Phase 2 NCT01031836 Japan;
MEDI-546
AstraZeneca
2021 Phase 3 EUCTR2020-004529-22-HU Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004529-22-BG Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 NCT01559090 Japan;
AstraZeneca AB
2017 Phase 3 EUCTR2016-000625-39-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Singapore;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000625-39-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Lithuania;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Astrazeneca AB
2016 Phase 2 EUCTR2016-003246-93-HU Hungary;Korea, Republic of;Poland;United States;
MedImmune, LLC
2013 Phase 2 EUCTR2011-004296-36-BG Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 - EUCTR2011-004296-36-HU Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2012 - EUCTR2011-004296-36-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hong Kong;Hungary;India;Israel;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
MEDI-570
MedImmune LLC
2010 Phase 1 NCT01127321 Canada;Mexico;Peru;South Africa;United States;
MHS552
Novartis Pharmaceuticals
2022 Phase 1 NCT05203419 -
MMF
Atsumi Tatsuya
2020 Phase 4 JPRN-jRCTs011190011 Japan;
MRA 003 US
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 Phase 1 NCT00046774 United States;
MRI, Venipuncture
NYU Langone Health
2002 Phase 2 NCT00412841 United States;
MRNA COVD19 vaccine
Mayo Clinic
2021 Early Phase 1 NCT04839315 United States;
MSC treatment
Universidad de los Andes, Chile
2019 Phase 2 NCT03917797 Chile;
MSC2364447C
EMD Serono Research & Development Institute, Inc.
2015 Phase 1 NCT02537028 Bulgaria;United States;
MT-1303 High dose
Mitsubishi Tanabe Pharma Corporation
2015 Phase 1 NCT02307643 Japan;
MT-1303 Low dose
Mitsubishi Tanabe Pharma Corporation
2015 Phase 1 NCT02307643 Japan;
MTX
Zhejinag University of f Chinese Medicine
2020 Phase 0 ChiCTR2000030247 China;
MYFORTIC*50CPR RIV
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
MabThera (Rituximab)
GlaxoSmithKline Research & Development Ltd
2018 Phase 3 EUCTR2016-003050-32-NL Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
2018 Phase 3 EUCTR2016-003050-32-DE Argentina;Brazil;Canada;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
GlaxoSmithKline, S.A.
2017 Phase 3 EUCTR2016-003050-32-ES Argentina;Brazil;Canada;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;United States;
Medi-546
AstraZeneca
2021 Phase 3 NCT04877691 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
MedImmune, LLC, a wholly owned subsidiary of AstraZeneca
2014 Phase 2 EUCTR2012-004619-30-BG Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-HU Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
2013 Phase 2 EUCTR2012-004619-30-CZ Brazil;Bulgaria;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Romania;Taiwan;Ukraine;United States;
Medroxyprogesterone
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Melatonin
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
2019 Phase 4 ChiCTR1900020803 China;
Memantine
Johns Hopkins University
2006 - NCT00181298 United States;
Vanderbilt University Medical Center
2018 Phase 2 NCT03527472 United States;
Mesenchymal stem cells
Assistance Publique - Hôpitaux de Paris
2019 Phase 1/Phase 2 NCT03562065 France;
Hebei Medical University
2017 Early Phase 1 NCT03219801 China;
Mesna
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Metformin
RenJi Hospital
2016 Phase 4 NCT02741960 China;
Renji Hospital, Shanghai JiaoTong University School of Medicine
2012 - ChiCTR-TRC-12002419 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INC-17011497 China;
Methotrexate
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Zhejiang Chinese Medical University
2015 - ChiCTR-ONC-15007547 China;
Methotrexate and folic acid
University Health Network, Toronto
1995 Phase 3 NCT00470522 Canada;
Methyl prednisolone
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
Methylprednisolone
Chinese SLE Treatment And Research Group
2015 Phase 3 NCT02444728 China;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
2006 Phase 3 NCT00381810 United States;
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Oklahoma Medical Research Foundation
2017 Phase 2 NCT03355482 United States;
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Methylprednisolone sodium succinate
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Milatuzumab
Gilead Sciences
2007 Phase 1 NCT01845740 United States;
Milnacipran
Loma Linda University
2011 Phase 4 NCT01359826 United States;
Mizoribine
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
Modafinil
Hospital for Special Surgery, New York
2006 - NCT00297284 United States;
Moderna mRNA-1273
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Mosunetuzumab
Hoffmann-La Roche
2022 Phase 1 NCT05155345 Moldova, Republic of;Ukraine;United States;
Moxifloxacin
Bristol-Myers Squibb
2018 Phase 1 NCT03541564 United States;
Multivitamin
Chinese University of Hong Kong
2008 Phase 4 NCT00508898 Hong Kong;
Mycophenolate mofetil
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-FR Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Guy's and St Thomas' NHS Foundation Trust
2006 Phase 4 NCT01101802 United Kingdom;
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Oklahoma Medical Research Foundation
2006 Phase 1/Phase 2 NCT00594932 United States;
Ruijin Hospital
2018 - ChiCTR1800017540 China;
The University of Hong Kong
2015 - JPRN-UMIN000025328 Japan,Asia(except Japan);
Mycophenolate mofetil (MMF)
Bristol-Myers Squibb
2007 Phase 2/Phase 3 NCT00430677 Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Japan;Korea, Republic of;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;United States;
Mycophenolate motetil
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Mycophenolic acid
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Myfortic
Cambridge University Hospitals NHS Foundation Trust
2005 Phase 2 EUCTR2005-002207-16-GB United Kingdom;
Novartis Pharma Services AG
2006 - EUCTR2005-003070-19-HU Hungary;
N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-001645-41-SE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-PL Argentina;Brazil;Chile;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-DE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2013 - EUCTR2012-001645-41-CZ Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 Phase 2 EUCTR2012-001645-41-EE Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Korea, Republic of;Peru;Poland;South Africa;Spain;Sweden;
2012 - EUCTR2012-001645-41-HU Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
2012 - EUCTR2012-001645-41-GR Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
GlaxoSmithKline, S.A.
2012 - EUCTR2012-001645-41-ES Argentina;Brazil;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Thailand;
N-acetylcysteine
State University of New York - Upstate Medical University
2021 Phase 2 NCT00775476 United States;
NNC 0151-0000-0000
Novo Nordisk A/S
2009 Phase 1 NCT01018238 United States;
2008 Phase 1 NCT02151409 Netherlands;
NNC0114-0006
Novo Nordisk A/S
2012 Phase 1 NCT01689025 Hungary;Poland;Serbia;United States;
NON APPLICABILE
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001567-25-IT Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
NOX-E36
NOXXON Pharma AG
2009 Phase 1 NCT00976729 United Kingdom;
Nelfinavir
Northwell Health
2014 Phase 2 NCT02066311 United States;
Nicotinamide
Second Xiangya Hospital of Central South University
2017 Phase 2 NCT03260166 China;
Nipocalimab
Janssen Research & Development, LLC
2021 Phase 2 NCT04882878 Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Janssen-Cilag International NV
2021 Phase 2 EUCTR2020-005569-14-HU Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-ES Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
2021 Phase 2 EUCTR2020-005569-14-BG Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Numaguchi Hirotaka
2022 Phase 2 JPRN-jRCT2041210058 Bulgaria;Colombia;Germany;Hungary;Japan;Poland;South Africa;Spain;Taiwan, Province Of China;Ukraine;United States OfAmerica;
Nivolumab
Alliance Foundation Trials, LLC.
2019 Phase 1 NCT03656627 United States;
National Cancer Institute (NCI)
2019 Phase 1 NCT03816345 Canada;United States;
Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Norethindrone
National Center for Research Resources (NCRR)
2000 - NCT00006133 United States;
Normal Saline
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
ORENCIA 125 mg solution for injection in pre-filled syringe
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Obinutuzumab
Hoffmann-La Roche
2021 Phase 3 NCT04963296 Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
Obinutuzumab administration
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04702256 France;
Ocrelizumab
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Genentech, Inc.
2008 Phase 3 NCT00626197 United States;
2007 Phase 3 NCT00539838 United States;
Olumiant
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 3 EUCTR2017-005028-11-IT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 3 EUCTR2017-005028-11-NL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-HR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 3 EUCTR2017-005028-11-GR Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-RO Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-PL Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-HU Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-GB Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Czech Republic;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-ES Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-DE Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-CZ Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005028-11-AT Argentina;Australia;Austria;Belgium;Brazil;Chile;China;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-NL Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-HR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GR Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Israel;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-005026-37-GB Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005027-25-ES Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
2018 Phase 3 EUCTR2017-005026-37-HU Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-CZ Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-BE Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-005026-37-AT Australia;Austria;Belgium;Brazil;China;Croatia;Czech Republic;Czechia;Germany;Greece;Hungary;Mexico;Netherlands;Russian Federation;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Olumiant - EU/1/16/1170/001-008
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Olumiant - EU/1/16/1170/009-016
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2018 Phase 3 EUCTR2017-005027-25-IT Argentina;Chile;Colombia;France;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Romania;Serbia;South Africa;Spain;United States;
Omacor
GreenPark Healthcare Trust
2004 Phase 4 EUCTR2004-004404-21-GB United Kingdom;
Omega-3
Michelle Petri M.D.,MPH
2009 Phase 4 NCT00828178 United States;
Oral Prednisone
University of Pisa
2019 - NCT03804723 -
Oral prednisolone
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
Orencia
Bristol-Myers Squibb International Corporation
2008 Phase 2;Phase 3 EUCTR2005-004575-37-GB Belgium;France;United Kingdom;
2007 Phase 2;Phase 3 EUCTR2005-004575-37-BE Belgium;France;United Kingdom;
Ortho-Novum 777
New York University School of Medicine
1997 Phase 3 NCT00000420 United States;
Oxygen
Guangdong Provincial Hospital of Chinese Medicine
2017 - ChiCTR-IOR-17012802 China;
Ozone
Guangdong Provincial Hospital of Chinese Medicine
2017 - ChiCTR-IOR-17012802 China;
P 140
IMMUPHARMA SA
2008 - EUCTR2007-004892-21-BG Bulgaria;Spain;
PAH
Guangdong Provincial People's Hospital
2020 - ChiCTR2000030342 China;
PF-04236921
Pfizer
2011 Phase 2 NCT01405196 Argentina;Chile;Colombia;Germany;Hungary;Korea, Republic of;Mexico;Moldova, Republic of;Peru;Poland;Puerto Rico;Romania;Taiwan;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 - EUCTR2011-000420-15-HU Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States;
2012 - EUCTR2011-000420-15-DE Argentina;Chile;Colombia;Germany;Hungary;India;Israel;Korea, Republic of;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Taiwan;United States;
PF-06700841
Pfizer
2019 Phase 2 NCT03845517 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
PF-06700841-15
PFIZER INC
2021 Phase 2 EUCTR2018-004175-12-IT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Pfizer Inc.
2019 Phase 2 EUCTR2018-004175-12-PT Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-PL Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-HU Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-GB Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-ES Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-DE Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-CZ Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-004175-12-BG Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
PF-06835375
Pfizer
2017 Phase 1 NCT03334851 Puerto Rico;United States;
Paquinimod
Active Biotech Research AB
2009 - EUCTR2009-011245-55-SE Denmark;Sweden;
2009 - EUCTR2009-011245-55-DK Denmark;Sweden;
Paquinimod (ABR-215757)
Active Biotech AB
2009 Phase 2 NCT00997100 Denmark;Sweden;
Phosphate-buffered saline
La Jolla Pharmaceutical Company
2004 Phase 3 NCT00089804 Argentina;Australia;Belarus;Brazil;Bulgaria;Czech Republic;Former Serbia and Montenegro;Georgia;Germany;Hong Kong;Hungary;India;Indonesia;Italy;Korea, Republic of;Lebanon;Malaysia;Mexico;Philippines;Poland;Portugal;Puerto Rico;Romania;Serbia;Slovakia;Spain;Sri Lanka;Taiwan;Thailand;Ukraine;United States;
Pioglitazone
National Heart Institute, Mexico
2007 Phase 4 NCT01322308 -
Pitavastatin
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Placebo
AstraZeneca
2017 Phase 3 JPRN-JapicCTI-173544 Japan, Asia except Japan, North America, South America, Europe, Oceania;
2016 Phase 3 JPRN-JapicCTI-153064 Japan, Asia except Japan, North America, South America, Europe, Africa;
Eli Lilly Japan K.K.
2016 Phase 2 JPRN-JapicCTI-163359 -
- Phase 3 JPRN-JapicCTI-184095 -
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183973 Japan, Asia except Japan, North America, South America, Europe, Africa;
Merck Biopharma Co., Ltd
2017 Phase 2 JPRN-JapicCTI-183957 Japan, Asia except Japan, North America, South America, Europe, Africa;
Plaquenil
Christine Bengtsson
2015 Phase 2 EUCTR2014-005418-45-SE Sweden;
Plasmapheresis
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Pneumovax
University of Alabama at Birmingham
2007 - NCT00611611 United States;
Polymorphism Analysis
Sun Yat-sen University
2010 - NCT01060410 China;
Pooled mesenchymal stem cell
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2019 Phase 1/Phase 2 NCT04184258 Belarus;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Prasterone (GL701)
Genelabs Technologies
2003 Phase 3 NCT00082511 Mexico;United States;
2002 Phase 3 NCT00053560 Mexico;United States;
Pravastatin
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Prednisolone
Atsumi Tatsuya
2020 Phase 4 JPRN-jRCTs011190011 Japan;
Japanese Study Group of Renal Disease in Children(JSRDC)
2006 - JPRN-C000000159 Japan;
1995 - JPRN-C000000378 Japan;
University Hospital Gent
- Phase 3 EUCTR2005-003957-28-BE Belgium;Denmark;Italy;
Zenyaku Kogyo Co., Ltd.
2007 - JPRN-UMIN000000639 Japan;
Prednisolone/Prednisone
Teva Branded Pharmaceutical Products R&D, Inc.
2010 Phase 2 NCT01085097 Canada;France;Russian Federation;United Kingdom;United States;
Prednisone
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 4 EUCTR2017-002050-36-FR France;
Ampel BioSolutions, LLC
2017 Phase 4 NCT03098823 United States;
Bristol-Myers Squibb
2005 Phase 2 NCT00119678 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Sweden;Taiwan;United Kingdom;United States;
Fairview University Medical Center
2000 - NCT00006055 United States;
Genentech, Inc.
2007 Phase 3 NCT00539838 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
ISTITUTO GIANNINA GASLINI
2006 - EUCTR2005-003957-28-IT Italy;
NOVARTIS FARMA
2006 - EUCTR2006-002107-13-IT France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01946880 United States;
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1986 Phase 2 NCT00001212 United States;
New York University School of Medicine
1997 Phase 2 NCT00000421 United States;
Peking University First Hospital
2021 Phase 0 ChiCTR2100048635 China;
Ruijin Hospital
2018 - ChiCTR1800017540 China;
University of Sao Paulo General Hospital
2018 - NCT03492255 Brazil;
Zhejinag University of Chinese Medicine
2008 Phase 3 study ChiCTR-TRC-12001935 China;
Prednisone acetate
Nanjing University of Chinese Medicine Affiliated Hospital
2019 Phase 1 study ChiCTR1800020286 China;
2019 Phase 1 ChiCTR1900022934 China;
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Prednisone discontinuation
Groupe Hospitalier Pitie-Salpetriere
2014 Phase 3 NCT02558517 France;
Premarin and Provera
New York University School of Medicine
1996 Phase 3 NCT00000419 United States;
Prevenar® and Pneumo23®
Assistance Publique - Hôpitaux de Paris
2008 Phase 2/Phase 3 NCT00611663 France;
Proleukin
Charité - Universitätsmedizin Berlin
2014 Phase 1;Phase 2 EUCTR2013-001599-40-DE Germany;
Quinipril
University Health Network, Toronto
2002 Phase 4 NCT00188188 Canada;
R-salbutamol sulphate
Astion Pharma A/S
2007 - EUCTR2007-004635-29-SE Denmark;Spain;Sweden;
2007 - EUCTR2007-004635-29-DK Denmark;Spain;Sweden;
R932333
Rigel Pharmaceuticals
2012 Phase 2 NCT01597050 Canada;United States;
RANKL/OPG ratio
Centre Hospitalier Universitaire, Amiens
2011 - NCT02799173 France;
RAYOS
Ampel BioSolutions, LLC
2017 Phase 4 NCT03098823 United States;
RC18 160 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RemeGen Co., Ltd.
2019 Phase 3 NCT04082416 China;
RC18 240 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RC18 80 mg plus standard therapy
RemeGen
2015 Phase 2 NCT02885610 China;
RECOMBINANT FACTOR FC FUSION PROTEIN
AMGEN INC.
2021 Phase 2 EUCTR2020-003509-72-IT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-002564-40-DE France;Germany;Poland;United States;
Amgen Inc.
2021 Phase 2 EUCTR2020-003509-72-PL Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-GR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-FR Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-ES Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-BG Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
2021 Phase 2 EUCTR2020-003509-72-AT Austria;Bulgaria;Canada;Chile;Colombia;France;Greece;Hong Kong;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United States;
RO 496-4913
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
RO7010939/F13
Genentech, Inc.
2018 Phase 2 EUCTR2017-001764-37-PT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001764-37-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-PT Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-ES Argentina;Brazil;Bulgaria;Chile;Colombia;France;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-DE Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001039-11-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001039-11-GB Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
Roche Farma, S.A por delegación de Genentech, Inc.
2017 Phase 2 EUCTR2017-001764-37-ES Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Korea, Republic of;Mexico;Portugal;Spain;Taiwan;United Kingdom;United States;
ROSUVASTATIN CALCIUM
Imperial College
2010 Phase 4 EUCTR2006-006214-16-GB United Kingdom;
RSLV-132
Resolve Therapeutics
2016 Phase 2 NCT02660944 United States;
2014 Phase 1 NCT02194400 United States;
Rabbit anti-thymocyte globulin
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
Rabbit antithymocyte globulin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
Ramipril
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Federal University of São Paulo
2011 Phase 2/Phase 3 NCT03979976 Brazil;
Rapamycin
State University of New York - Upstate Medical University
2008 Phase 2 NCT00779194 United States;
the Second Hospital of Shanxi Medical University
2016 - ChiCTR-IPR-16009451 China;
Raptiva
Universitätskrankenhaus Schleswig-Holstein
2009 - EUCTR2008-003833-25-DE Germany;
Recombinant zoster vaccine
RenJi Hospital
2021 - NCT04516408 China;
Reduced Intensity Allogeneic Transplant
New York Medical College
2007 Phase 1 NCT00684255 United States;
Remicade
Department of Rheumatology, Internal Medicine III, Medical University of Vienna
2006 - EUCTR2005-004067-30-NL Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-DE Austria;Germany;Netherlands;
2006 - EUCTR2005-004067-30-AT Austria;Germany;Netherlands;
RhuMAb 2H7
F. Hoffmann-La Roche Ltd
2008 Phase 3 EUCTR2006-005357-29-GB Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2006-005355-16-PL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-SE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-PT Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-NL Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-DE Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005357-29-BG Bulgaria;France;Germany;Hungary;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-SE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-PT France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-NL France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-GB France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005355-16-DE France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-HU Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005357-29-FR Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005355-16-FR France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005355-16-HU France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2006-005357-29-PL Bulgaria;France;Germany;Hungary;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
RhuMAb IFNalpha
Genentech, Inc.
2007 Phase 1 NCT00541749 United States;
Rigerimod
Cephalon, Inc.
2010 Phase 2 EUCTR2010-018383-16-FR Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 Phase 2 EUCTR2010-018383-16-ES Belgium;Czech Republic;France;Germany;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-HU Czech Republic;Hungary;Portugal;Spain;
2010 - EUCTR2010-019293-32-ES Czech Republic;Germany;Hungary;Portugal;Spain;
Rituxan (rituximab)
National Cancer Institute (NCI)
2004 Phase 2 NCT00076752 United States;
Rituximab
Assiut University
2021 Phase 3 NCT05057481 Egypt;
Cambridge University Hospitals NHS Foundation Trust
2002 Phase 2 NCT00293072 United Kingdom;
Chinese University of Hong Kong
2006 Phase 2 NCT00556192 China;
European Society for Blood and Marrow Transplantation
2009 Phase 2/Phase 3 NCT05063513 France;
Genentech, Inc.
2006 Phase 3 NCT00381810 United States;
2005 Phase 2/Phase 3 NCT00137969 Canada;United States;
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Imperial College London
2015 Phase 3 NCT01773616 United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2005 Phase 2 NCT00230035 United States;
2001 Phase 1/Phase 2 NCT00036491 United States;
University of Leeds
2017 Phase 2 NCT03054259 United Kingdom;
Zenyaku Kogyo Co., Ltd.
2007 - JPRN-UMIN000000763 Japan;
Rivaroxaban
University College London
2019 Phase 2;Phase 3 EUCTR2018-001735-49-GB United Kingdom;
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
University College, London
2020 Phase 2/Phase 3 NCT03684564 -
Ro 106-1443
Guy's & St Thomas' NHS Foundation Trust
2005 Phase 4 EUCTR2005-001688-74-GB United Kingdom;
Rontalizumab
Chugai Pharmaceutical Co., Ltd.
2012 Phase 1 JPRN-JapicCTI-121864 -
Genentech, Inc.
2009 Phase 2 NCT00962832 Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom;United States;
Rosuvastatin
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Imperial College London
2010 Phase 2 NCT01170585 United Kingdom;
Ramathibodi Hospital
2008 Phase 4 NCT00866229 Thailand;
Tuen Mun Hospital
2006 Phase 4 NCT00371501 Hong Kong;
Royal jelly
Faculty of medicine, University of Assiut, Assiut 71516, Egypt.
2015 - JPRN-UMIN000020859 Africa;
Rozibafusp Alfa
Amgen
2020 Phase 2 NCT04058028 Argentina;Australia;Bulgaria;Canada;Czechia;France;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Spain;United States;
SAR113244
Sanofi
2016 Phase 1 NCT02331810 -
2014 Phase 1 NCT02321709 Germany;
SAR441344
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001567-25-IT Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
Sanofi-Aventis Recherche et Développement
2021 Phase 2 EUCTR2021-001567-25-ES Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2021-001567-25-DE Argentina;Chile;Germany;Greece;Italy;Mexico;Russian Federation;Spain;Turkey;Ukraine;United States;
SAR441344 IV
Sanofi
2021 Phase 2 NCT05039840 United States;
SAR441344 SC
Sanofi
2021 Phase 2 NCT05039840 United States;
SBI-087
Pfizer
2009 Phase 1 NCT00714116 Canada;United States;
SC belimumab
GlaxoSmithKline
2017 - NCT03125486 United States;
SM101
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
SM934
RenJi Hospital
2019 Phase 2 NCT03951259 China;
SQ Fludarabine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1998 Phase 1 NCT00001676 United States;
STELARA®
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
Sifalimumab
ASTRAZENECA
2011 - EUCTR2010-024069-30-IT Argentina;Brazil;Bulgaria;Canada;Chile;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;South Africa;Spain;Thailand;United Kingdom;United States;
AstraZeneca AB
2012 - EUCTR2010-024069-30-BG Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 Phase 2 EUCTR2010-024069-30-GB Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-NL Argentina;Brazil;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-ES Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
2011 - EUCTR2010-024069-30-DE Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
- - EUCTR2010-024069-30-HU Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
MedImmune LLC
2010 Phase 2 NCT00979654 Brazil;Canada;Chile;United States;
Sifalimumab 1,
MedImmune LLC
2011 Phase 2 NCT01283139 Argentina;Brazil;Bulgaria;Canada;Chile;France;Germany;Hungary;India;Italy;Jamaica;Mexico;Netherlands;Peru;Philippines;Poland;Romania;South Africa;Spain;Thailand;United Kingdom;United States;
Simvastatin
GlaxoSmithKline
2013 Phase 1 NCT01953835 United States;
Merck Sharp & Dohme Corp.
2007 Phase 4 NCT00739050 -
Ramathibodi Hospital
2008 Phase 4 NCT00866229 Thailand;
Sirolimus
Chinese SLE Treatment And Research Group
2020 Phase 2 NCT04582136 -
State University of New York - Upstate Medical University
2021 Phase 2 NCT04736953 -
Soluble Fc receptor
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
Soluble Fc-gamma receptor IIb
SuppreMol GmbH
2012 - EUCTR2010-023396-25-PL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2012 - EUCTR2010-023396-25-NL Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-GB Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-023396-25-BE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-ES Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-DE Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
2011 - EUCTR2010-023396-25-CZ Australia;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;
Standard dose of HCQ
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
Standard dose of rituximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 4 NCT04127747 China;
Standard of care
Peking Union Medical College Hospital
2021 Phase 4 NCT04956484 China;
Standard therapy
GlaxoSmithKline
2021 Phase 4 NCT04908865 -
Human Genome Sciences Inc., a GSK Company
2011 Phase 3 NCT01484496 Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Malaysia;Mexico;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;United States;
RemeGen Co., Ltd.
2022 Phase 1 NCT05247203 China;
Standard therapy (Excluding Immunosuppressants)
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Standard therapy (Including Immunosuppressants)
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Standard-of-care treatment
Janssen Research & Development, LLC
2021 Phase 2 NCT04882878 Argentina;Bulgaria;Colombia;Germany;Hong Kong;Hungary;Japan;Poland;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United States;
Stelara
Janssen-Cilag International NV
2019 Phase 3 EUCTR2017-001489-53-PT Argentina;Bulgaria;Canada;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-PL Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-LT Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-HU Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-ES Argentina;Australia;Bulgaria;China;Colombia;Ecuador;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-DE Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
2018 Phase 3 EUCTR2017-001489-53-BG Argentina;Bulgaria;Canada;China;Colombia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
Steroid Drug
Mallinckrodt
2013 Phase 4 NCT01753401 United States;
Steroid Taper
GlaxoSmithKline
2018 Phase 3 NCT03312907 Argentina;Brazil;Canada;France;Germany;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United States;
Subcuvia
Department of Rheumatology,University hospital,Lund
2007 - EUCTR2006-004892-36-SE Sweden;
Sugar pill
Guy's and St Thomas' NHS Foundation Trust
2006 Phase 4 NCT01101802 United Kingdom;
Sulfate
The Third Affiliated Hospital, Southern Medical University
2018 - ChiCTR1800019308 China;
Switch to Myfortic
Erasmus Medical Center
2007 Phase 3 NCT00504244 Netherlands;
TAB08
Theramab LLC
2016 Phase 2 NCT02711813 Russian Federation;
TACI-Fc5
Merck Serono International
2008 - EUCTR2007-003698-13-BG Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-FR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003698-13-ES Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany
2008 Phase 2;Phase 3 EUCTR2007-003698-13-GB Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-NL Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-LV Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-LT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
2008 - EUCTR2007-003698-13-GR Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003698-13-CZ Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Spain;Taiwan;United Kingdom;United States;
- - EUCTR2007-003698-13-DE Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;India;Israel;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Serbia;Spain;Switzerland;Taiwan;United Kingdom;United States;
Merck Serono SA - Geneva
2008 - EUCTR2007-003698-13-AT Austria;Bulgaria;Czech Republic;France;Germany;Greece;Latvia;Lithuania;Netherlands;Spain;United Kingdom;
TAK-079
Millennium Pharmaceuticals, Inc.
2018 Phase 1 NCT03724916 United States;
TJ202 injection
I-Mab Biopharma Co. Ltd.
2021 Phase 1 NCT05140824 China;
TLR7/8 Antagonist (10mg)
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
TLR7/8 Antagonist (2.5mg)
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-004021-25-PL Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-FR Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-004021-25-ES Argentina;Australia;Brazil;Chile;Colombia;France;Germany;Ireland;Japan;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
TRU-015
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 1 NCT00479622 United States;
TV-4710
TEVA
2005 - EUCTR2005-001391-12-IT Germany;Hungary;Italy;Spain;United Kingdom;
TEVA Pharmaceutical Industries, Ltd.
2005 Phase 2 EUCTR2005-001391-12-GB Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2005-001391-12-ES Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-HU Germany;Hungary;Italy;Spain;United Kingdom;
2005 - EUCTR2005-001391-12-DE Germany;Hungary;Italy;Spain;United Kingdom;
Tabalumab Auto-Injector
Eli Lilly and Company
2014 Phase 3 NCT02041091 Korea, Republic of;Mexico;Puerto Rico;United States;
Tabalumab Prefilled Syringe
Eli Lilly and Company
2014 Phase 3 NCT02041091 Korea, Republic of;Mexico;Puerto Rico;United States;
Tacrolimus
Chinese University of Hong Kong
2004 Phase 4 NCT00125307 China;Hong Kong;
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2010 - JPRN-UMIN000004182 Japan;
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016 Phase 1/Phase 2 NCT02080195 United States;
The University of Hong Kong
2015 - JPRN-UMIN000025328 Japan,Asia(except Japan);
Telitacicept
RemeGen Co., Ltd.
2022 Phase 1 NCT05247203 China;
Thalidomide
University of Sao Paulo General Hospital
2017 Phase 4 NCT03122431 Brazil;
The generic name is warfarin and many producers will be involved
University College London
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
Tocilizumab
Hoffmann-La Roche
2022 Phase 1 NCT05155345 Moldova, Republic of;Ukraine;United States;
Tocopherol acetate
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
2014 Phase 2 JPRN-UMIN000008230 Japan;
Nakashima Yasuharu
2014 Phase 2 JPRN-jRCTs071180052 Japan;
Toctino®
Universitätsklinikum Münster
2011 - EUCTR2010-024131-16-DE Germany;
Tofacitinib
Children's Hospital Medical Center, Cincinnati
2017 Phase 1/Phase 2 NCT03288324 United States;
National Institute of Allergy and Infectious Diseases (NIAID)
2022 Phase 1 NCT05048238 United States;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2015 Phase 1 NCT02535689 United States;
Tofacitinib citrate
Tufts Medical Center
2017 Early Phase 1 NCT03159936 United States;
Trade Name Xarelto
University College London
2019 Phase 2;Phase 3 EUCTR2018-001735-49-GB United Kingdom;
Trade name Xarelto
University College London
2012 Phase 2 EUCTR2012-002345-38-GB United Kingdom;
Trimethoprim-Sulfamethoxazole
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2017 Phase 4 NCT03042260 Mexico;
Triptorelin pamoate
Children's Hospital Medical Center, Cincinnati
2003 Phase 2 NCT00124514 Brazil;United States;
Upadacitinib
AbbVie
2020 Phase 2 NCT04451772 Argentina;Australia;Bulgaria;Canada;China;Colombia;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2019 Phase 2 NCT03978520 Argentina;Australia;Bulgaria;Canada;China;Colombia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
Yamazaki Hayato
2020 Phase 2 JPRN-jRCT2031210119 Argentina;Bulgaria;China;Germany;Hungary;Japan;Mexico;Netherlands;Poland;Puerto Rico;Spain;Taiwan;United States;
Urine sample
University Hospital, Bordeaux
2018 - NCT03575156 France;
Ustekinumab
Janssen Pharmaceutical K.K.
2018 Phase 3 JPRN-JapicCTI-183973 Japan, Asia except Japan, North America, South America, Europe, Africa;
Janssen-Cilag International N.V.
2015 Phase 2 EUCTR2014-005000-19-PL Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-HU Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-ES Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
2015 Phase 2 EUCTR2014-005000-19-DE Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United States;
Ustekinumab (approximately 6 mg/kg)
Janssen Research & Development, LLC
2020 Phase 3 NCT04060888 China;
2018 Phase 3 NCT03517722 Argentina;Australia;Bulgaria;Canada;China;Colombia;Ecuador;France;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Ukraine;United States;
Ustekinumab 90 milligram (mg)
Janssen Research & Development, LLC
2020 Phase 3 NCT04060888 China;
Ustekinumab IV
Janssen Research & Development, LLC
2015 Phase 2 NCT02349061 Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States;
Ustekinumab SC
Janssen Research & Development, LLC
2015 Phase 2 NCT02349061 Argentina;Australia;Germany;Hungary;Mexico;Poland;Spain;Taiwan;United Kingdom;United States;
VAY736
Novartis Farmacéutica, S.A.
2018 Phase 2 EUCTR2018-001508-12-ES Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharma AG
2019 Phase 2 EUCTR2018-001508-12-FR Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
2018 Phase 2 EUCTR2018-001508-12-DE Argentina;Australia;China;Czech Republic;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
2018 Phase 2 EUCTR2018-001508-12-CZ Argentina;Australia;China;Czech Republic;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;
Novartis Pharmaceuticals
2018 Phase 2 NCT03656562 Argentina;Australia;China;Czechia;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Thailand;United States;
VIB7734
Viela Bio
2021 Phase 2 NCT04925934 Argentina;Greece;Mexico;Poland;Spain;Ukraine;United States;
2018 Phase 1 NCT03817424 Poland;Spain;United States;
VIB7734, MEDI7734
Viela Bio, Inc.
2021 Phase 2 EUCTR2020-005528-12-ES Argentina;Greece;India;Mexico;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
VIP
MONDOGEN AG
2008 - EUCTR2007-003621-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
MondoGEN AG
2009 - EUCTR2007-003621-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2007-003621-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003621-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Vaccination
Tuen Mun Hospital
2015 - NCT02477254 China;
Vaccine
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT01072734 France;
Versus hydroxychloroquine
Assistance Publique - Hôpitaux de Paris
2007 Phase 4 NCT00413361 France;
Vitamin D
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
2017 - ChiCTR-INR-17011495 China;
Vitamin D 25(OH)D
Faculty of Medicine, University of Alexandria
2010 - NCT01425775 Egypt;
Vitamin D2 ( calciferol )
Rajavithi Hospital
2021 - NCT05260255 Thailand;
Vitamin D3
National Institute of Allergy and Infectious Diseases (NIAID)
2008 Phase 2 NCT00710021 United States;
Vitamin D3 400 IU
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01709474 United States;
Vitamin D3 6000 IU
National Institute of Allergy and Infectious Diseases (NIAID)
2013 Phase 2 NCT01709474 United States;
Vitamins: B6, B12, and folate
Brigham and Women's Hospital
2003 Phase 2 NCT00054938 United States;
Vobarilizumab
Ablynx N.V.
2015 Phase 2 EUCTR2015-000372-95-HU Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-DE Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
2015 Phase 2 EUCTR2015-000372-95-CZ Argentina;Chile;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Peru;Philippines;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United States;
Warfarin
University College, London
2020 Phase 2/Phase 3 NCT03684564 -
XmAb5871
Xencor, Inc.
2016 Phase 2 NCT02725515 United States;
Zishenqing
Shanghai University of Traditional Chinese Medicine
2019 Phase 2/Phase 3 NCT04275193 China;
Zostavax
Tuen Mun Hospital
2015 Phase 4 NCT02477150 China;
Zostavax vaccine
Oklahoma Medical Research Foundation
2011 Phase 1 NCT01474720 United States;